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Molecular imaging is a powerful, noninvasive technique for patient stratification 
and treatment monitoring via cancer biomarker characterization with reporter probes. 
Small scaffold proteins that combine stable frameworks with diversifiable paratope regions 
are well-suited as engineerable probes for molecular imaging and often benefit from 
efficient physiological transport. Probe efficacy depends not only on diseased region 
localization but also passive noninteraction with plasma molecules and healthy tissues. 
Precise relationships between protein charge, physicochemical robustness, and in vivo 
performance are poorly understood, but the appropriate manipulation of ionic charge can 
stabilize native protein folds and reduce nonspecific interactions. Therefore, the effective 
engineering of protein charge in diagnostic molecular probes would advance cancer 
characterization and personalized medicine. 
In this thesis work we enlisted affibody and Gp2 proteins as molecular imaging 
scaffolds, applied discrete protein engineering designs to modify charge density and 
distribution, and evaluated promising charge-modified variants as positron emission 
tomography (PET) imaging agents in preclinical studies against the cancer biomarker, 
epidermal growth factor receptor (EGFR). Natural and functional (synthetic) homolog 
frequencies guided the design of charge-modified consensus clones and combinatorial 
libraries based on a hybrid anti-EGFR affibody, EA68; a synthetic consensus design proved 
most robust by providing variants that retain parental recombinant yield and stability while 
improving EGFR affinity. Charge-mutated combinatorial Gp2 libraries were enriched for 
binding against three clinically or biotechnologically relevant targets and revealed target-
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dependent total, net, and site-specific charge preferences demonstrating the utility of 
multitarget screening to determine globally accepted framework mutations. In summary, 
hybrids of combinatorial library selection and sequence informatics-driven design have 
proven effective for charge engineering. 
Preclinical investigation of lead anti-EGFR affibody and Gp2 clones and their 
charge-varied homologs in mice bearing EGFRhigh and EGFRlow tumor xenografts exposed 
differences in clonal biodistribution, tumor targeting, and proteolytic stability. Among 
tested variants, the charge-reduced affibody ‘EA35S’ and Gp2 ‘GαE35’ achieved the best 
overall performance with high (12 ± 2 %ID/g and 5.5 ± 0.5%ID/g) and specific 
(tumor:muscle = 34 ± 5 and 35 ± 5; tumor:blood = 12 ± 3 and 9.7 ± 1.3) EGFRhigh tumor 
localization at 4 and 2 h post-injection.  
Collectively, this work provides a suite of tools to maintain and enhance protein 
function through ionic charge engineering and reveals two promising probes for cancer 
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Chapter 1 - Introduction 
1.1. Proteins provide diverse functionality 
Proteins are a versatile class of molecules that have proven effective in industrial 
and biotechnological catalysis, targeted clinical therapy and diagnostics, and other 
applications. Degradative enzymes including amylases, lipases, phytases, and proteases are 
widely used in food1, detergent2, textile3, animal feed4, and biofuel industries5. To improve 
or alter their catalytic function, protein engineering has been used to enhance thermal 
stability6–8, tolerance to acidic9 and basic5 conditions, and stereoselectivity10. Additionally, 
numerous proteins are employed in fundamental biotechnological applications such as 
fluorescent reporter molecules11,12, polymerases13 and ligases14 for DNA manipulation, and 
peroxidases and phosphatases in antigen detection assays15.  
The utilization of proteins in medical research, therapy, and diagnostics is 
substantial. Peptide-based biopolymers including elastin-like polypeptides, leucine zipper 
hydrogels, and silk-like polymers have been designed to deliver cytotoxic loads under 
localized hyperthermia near tumors16, retard the in vivo release of therapeutics 17, and form 
self-assembling hydrogels as scaffold materials for tissue engineering18,19. Antimicrobial, 
antiviral, and cell-penetrating peptides are used to selectively combat gram-positive20 and 
gram-negative21,22 bacterial pathogens, inhibit viral infections23,24, and intracellularly 
transport therapeutic cargo25,26. Antibodies have been engineered to inhibit native receptor-
ligand interactions27,28, bridge tumor cells and immune cells to enhance interaction29, and 
deliver drugs to receptor-expressing tumor cells30 in monovalent, bispecific, and protein-
drug conjugate formats, respectively. Over 200 monoclonal and polyclonal antibodies are 
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available for use in immunohistochemical staining assays to detect cancer cell cycle, 
angiogenic, apoptotic, and patient stratifying antigens.31–34 As such, an understanding of 
the protein sequence/function relationship to enable the engineering of proteins for such 
applications is an important area for scientific and technological development. 
1.2. Protein engineering must balance numerous functions and properties 
The utility of a protein is dependent upon not only its core function of molecular 
binding, enzymatic catalysis, or material strength but also upon the physicochemical 
robustness of the protein and its ability to passively lack interaction with nontarget, 
nonsubstrate molecules in its environment. Numerous auxiliary characteristics influence 
protein performance including structural stability35, size36, solubility37, hydrophobicity38, 
ionic charge39, target discrimination40, and physiological transport kinetics41,42 with 
considerable interplay between each of these attributes. Engineering of useful proteins with 
enhanced or novel function requires consideration of these factors. 
Retention of native structure is a common prerequisite for proper protein function43, 
but the phenotypical diversity required for novel or enhanced functionality may necessitate 
mutations that destabilize the protein fold44. Antecedent thermodynamic stabilization 
promotes efficient discovery by increasing mutational tolerance.45 Additionally, thermal 
and chemical stability provide resistance to denaturation during stringent biotechnological 
processes, maintaining functional potency and allowing for repeated usage. Improving 
proteolytic resistance, which often correlates to increased thermal stability46, is critical for 
enzymes that are mixed with proteases during industrial applications47. Limiting the 
formation of insoluble multimers (inclusion bodies) during prokaryotic expression 
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increases recombinant protein yield, mitigating the need for expensive denaturation and 
refolding procedures.48 Furthermore, protein aggregates may be toxic49 in vivo and are 
associated with an elevated immune response50. Both the stabilization of native 
structures51,52 and modification of “sticky” hydrophobic patches in well-folded proteins53 
are valuable methods by which to hinder aggregation. 
Prevention of nonsubstrate and nontarget interactions reduces undesirable 
enzymatic byproducts, improves drug therapeutic indices, and increases contrast for 
disease state imaging. While specific off-target interactions may be reduced with advanced 
knowledge of interfacial residues40, physicochemical properties such as size, surface area, 
and hydrophobicity are often better suited to address broad nonspecificity. Proteins 
administered for therapeutic and detection purposes, such as antibodies and antibody-
derived fragments, often possess hydrophilic surfaces which cause them to tarry in blood 
and interstitial space before excretion. As such, scaffolds with molecular weights below 
the glomerular filtration cut-off (~ 50 kDa) undergo rapid plasma clearance36 thereby 
reducing instances of undesirable nontarget interactions. Additionally, small proteins and 
peptides bear less surface area, reducing the potential for unwanted protein interfaces. 
While the relationship between protein hydrophobicity and biodistribution is not well-
understood and often scaffold dependent54,55, hydrophobicity has been positively and 
negatively correlated with hepatic and renal signal, respectively38 suggesting a method by 
which excretory organ retention may be altered. 
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1.3. Ionic charge impacts protein performance yet is difficult to engineer 
The physicochemical property of primary interest in this thesis is ionic charge, 
which impacts performance by altering protein stability, solubility, and in vivo 
biodistribution and pharmacokinetic profile. Under aqueous conditions, the introduction of 
an ionizable functional group from an electrically charged amino acid into the hydrophobic 
interior of a folded protein is typically destabilizing.56–58 As such, charged residues often 
reside in solvent exposed positions to impart thermodynamic stability and avoid the 
energetic penalty associated with desolvation.59,60 However, internal acidic and basic 
residues are commonly required for enzymatic transduction pathways, which necessitates 
protein structure with high thermostability to retain functionality.56 Ionizable residues also 
affect the relative strength of intramolecular hydrogen bonds. Charge-stabilized hydrogen 
bonds are, on average, ~2 kcal mol-1 stronger than neutral hydrogen bonds.61 Electrostatic 
attraction between oppositely charged functional groups contribute several kcal mol-1 to 
scaffold stability in both long-distance coulombic interactions62,63 and short-distance (≤ 4 
Å) ion pairs64,65. Solubility is also impacted by net charge. The isoelectric point, or pH at 
which a protein carries no net charge, is dependent upon acid dissociation contributions 
from charged amino acids within the molecule. In solutions with a pH near the protein’s 
isoelectric point charges are balanced, causing a reduction in repulsive electrostatic forces 
and increased aggregation and precipitation.66 Additionally, patches of positive surface 
charge have been implicated in reduced protein solubility during production in prokaryotic 
expression systems due to nucleic acid binding.67 
Ionic charge significantly impacts protein performance in vivo, affecting ligand 
specificity, vascular permeability, tumor uptake, systemic clearance rates, and 
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biodistribution. Mammalian cell membranes are natively negative due, in part, to 
glycosylation of surface proteins and lipids. Highly positive proteins have been shown to 
interact nonspecifically with anionic cell membranes68–71 causing undesirable nontarget 
localization. Furthermore, repellent electrostatic interactions between the ligand 
paratope72,73 or nonparatope74 regions with an antigen or epitope of interest can be 
thermodynamically unfavorable, hindering molecular recognition efforts. Cationic charge 
has been linked to an increase in solid tumor extravasation and retention for IgG75, 
albumin76, liposomes77, and nanoparticles78 as well as an elevation in plasma clearance75. 
However, highly anionic branched polypeptides also demonstrated rapid clearance 
suggesting an abstruse relationship between charge directionality and systemic retention.39 
Electric charge also impacts anatomical biodistribution. Highly cationic and anionic states 
have amplified renal retention for cystine knots79, affibodies with chelator 
modifications80,81, branched polypeptides39, and bombesin analogs82. Conflictingly, 
reduced total protein charge was ineffective at modifying renal uptake in both hydrophilic 
and hydrophobic fibronectin domains, but a decrease in formal positive charge was 
associated with a drop in kidney retention.38 Increases in both negative and positive charge 
through succinylation or amidation of polypeptides39 or bovine serum albumin83 resulted 
in elevated hepatic retention. Anti-Tac Fab fragments with increased positive or negative 
charge yield a two-fold increase in lung absorption or three-fold higher stomach 
localization, respectively.84 Taken together, these outcomes suggest a complex relationship 




The ability to modulate charge to enhance physicochemical robustness and 
environmental passivity while retaining or enhancing function is a challenging, but 
achievable, goal. Naturally occurring proteins were often evolved for functionality rather 
than thermal stability85,86 and interventional residue mutagenesis typically results in further 
destabilization87,88. To overcome stability penalties upon charge mutation while retaining 
or improving functionality, researchers have relied on protein engineering techniques 
including rational design, semi-rational design, and directed evolution.89 Rational design 
and consensus modeling of charge-reversing or neutralizing mutations across surface 
residues has been successfully used to increase protein solubility90,91 and stability57,63. 
Raghunathan et al. were able to explore surface charge modulation on the green fluorescent 
protein (GFP) without affecting its native fluorescence through co-introduction of known 
stabilizing mutations.92 Neutral-to-charged residue mutations near the active site of 
Pseudomonas glumae lipase reduced its proteolytic susceptibility to substilin 5-fold 
compared to wild-type with minimal impact on catalytic activity.47 Through directed 
evolution, Pédelacq et al. discovered two mutations, E40K and G33D, which increased the 
solubility of nucleoside diphosphate kinase 50-95% by improving charge distribution and 
hydrogen bonding.93 Site-directed mutagenesis of a single, solvent-exposed position on 
ribonuclease Sa from tryptophan to aspartic or glutamic acid increased solubility nearly 
12-fold near the proteins isoelectric point.91 In silico stability analysis of the DNA-binding 
Sso7d protein by Traxlmyer et al. was used to reduce the net formal charge of Sso7d from 
+7 to +1 through basic residue neutralization and C-terminal lysine deletions while 
retaining parental clone hyperthermostability.73 
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Charge engineering is also an effective tool to alter protein physiological 
distribution and pharmacokinetics. The replacement of a single alanine with glutamic acid 
on the C-terminal linker region significantly increased tumor uptake in a bombesin peptide 
analog. However, adding two more glutamic acids to the linker abrogated this benefit and 
elevated renal retention.82 Elimination of either arginine or glutamic acids from the 
mercaptoacetyl-based technetium chelator of an anti-HER2 affibody caused a substantial 
reduction in renal retention at 4 h post-injection.80,81 Mutation of one or two arginine 
residues to glutamic acids in the 10th type III domain of human fibronectin did not decrease 
renal  signal.94 However, a more substantial charge removal lowered kidney signal 
independent of clonal hydrophobicity.38 Replacement of 7 neutral positions with acidic 
residues in the variable domain of the LMB-2 immunotoxin reduced liver uptake, causing 
a 3-fold decrease in hepatic necrosis without altering CD25 binding affinity.95 Modifying 
the hexa-histidine purification tag to alternate between histidine and glutamic acids ‘(HE)3’ 
reduced hepatic uptake nearly 6-fold in ZHER2:342 affibodies
96 with a similar, but less 
pronounced effect seen in the ADAPT scaffold97. 
Although successfully implemented in the examples listed, engineering of charge 
remains difficult and can be particularly challenging in the context of a small protein38,90 
where mutations encompass a significant fraction of the protein structure98. Precise 
relationships between protein charge, physicochemical properties, and in vivo performance 
remain elusive. In this thesis, we apply protein charge engineering to molecular targeting 
ligands within the context of PET imaging of epidermal growth factor receptor in cancer. 
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1.4. Molecular recognition improves noninvasive cancer patient stratification 
Cancer is the second leading cause of the death in the United States with 
approximately 1 in 3 Americans developing an invasive malignancy during their lifetime. 
The overall cancer death rate in the U.S. has decreased by 26% from its peak in 1991 due 
to an upsurge in smoking cessation, utilization of detection strategies such as mammograms 
and colonoscopies, and advances in oncological treatments.99 Mortality rates among 
several common types including lung, colorectal, breast (female), and prostate cancers 
have seen a steady decline in recent years.100 However, rates in liver, uterine, and brain 
malignancies have increased101 and an estimated 1.7 million new cancer diagnoses are still 
expected in 2018 resulting in roughly 610,000 deaths.99 Therefore, considerable effort is 
still necessary for the advancement of cancer diagnosis, prognosis, and treatment options. 
Traditional oncological treatments, such as chemotherapy, were not designed to be 
molecularly specific, relying instead on the high tumoral growth rate found in several 
cancers102 to exercise cytotoxicity, resulting in associated damage to healthy cells and 
limited efficacy for slow-growing and heterogeneous tumors. In recent years, precision 
medicine has begun to take advantage of advancements in the genetic, proteomic, and 
metabolic profiling of cancers to stratify disease status, determine the most efficacious 
treatment plan, and tailor medicinal doses appropriately. 
The molecular characterization of cancer through biomarker expression is a 
powerful method of predicting therapeutic response and improving patient outcome.103 
Therapeutic benefit from paclitaxel in node-positive breast cancer patients was associated 
with human epidermal growth factor receptor 2 expression, regardless of estrogen receptor 
status.104 Positive treatment response to bevacizumab in patients with advanced gastric 
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cancer correlated to high baseline plasma levels of vascular endothelial growth factor-A 
and low expression of neuropilin-1.105 The addition of onartuzumab to erlotinib treatment 
significantly improved progression-free and overall survival rates in patients with non-
small cell lung cancer that over-expressed the tyrosine-protein kinase Met, independent of 
gene expression.106 
A biomarker that has garnered considerable clinical interest is the epidermal growth 
factor receptor (EGFR), also known as HER1 or ErbB1. EGFR is a transmembrane 
glycoprotein containing an extracellular receptor domain and intracellular cytoplasmic 
tyrosine kinase domain whose dysregulation has been implicated in tumor survival, growth, 
and metastasis.107 Upon agonistic ligand binding or due to overexpression, EGFR 
homodimerization or intrafamilial heterodimerization with other ErbB receptors activates 
downstream events associated with oncogenic cell proliferation and apoptotic resistance 
including Ras-Raf-MEK-ERK, AKT-PI3K, and PLC-γ1-PKC pathways.108 Elevated 
EGFR levels are common among the majority of solid tumors107 with overexpression a 
strong prognostic indicator of poor patient outlook in head and neck, ovarian, cervical, 
esophageal, and bladder cancers109. EGFR expression levels and gene copy number are 
predictors of clinical response to receptor (cetuximab) and tyrosine kinase (gefitinib, 
icotinib) inhibiting treatments in primary and metastatic colorectal, non-small-cell lung, 
and esophageal cancers.110–114 In patients with HER2-positive primary breast cancer  EGFR 
surface overexpression, but not copy number, was associated with poor disease-free 
survival and predictive of response to trastuzumab therapy.115 Therefore, molecular 
imaging of EGFR could aid in the stratification of responders versus nonresponders to 
targeted therapies across a range of cancer types. While several probes have undergone 
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preclinical trials94,116,117, further development and discovery is necessary as there are no 
clinical EGFR imaging probes. 
Frequently, upon diagnosis and to aid in personalized treatment planning, biopsies 
of the primary tumor site are extracted and histological analysis used to differentiate by 
cancer type through cell structural abnormalities, antigen presence, genetic mutation, and 
genomic expression levels. Although a gold standard in cancer characterization, biopsies 
suffer from several drawbacks. Biomarker expression levels can differ between primary 
and metastatic tumor sites within the same patient118,119 leading to designed treatment plans 
with unpredictable efficacy towards satellite tumors. Furthermore, recent comprehensive 
genomic analyses has revealed the occurrence of intratumoral heterogeneity which may 
provide phenotypical diversity necessary to resist singular oncological treatments, 
suggesting a need for continued molecular characterization during treatment.120,121 
Unfortunately, repeated biopsies are often unfeasible due to financial and quality of life 
concerns. To address this need, considerable effort has been made into noninvasive 
diagnostic imaging. 
Traditional diagnostic imaging lacks molecular specificity. Cross-sectional 
imaging techniques including magnetic resonance (MRI), computed tomography (CT), and 
ultrasonography (Ultrasound) rely on anatomical, physiological, or metabolic phenomena 
as contrast agents to distinguish between healthy and diseased states. In recent years, the 
field of molecular imaging has emerged to address the shortcomings in sensitivity and 
specificity of traditional imaging through the molecular-level targeting. Imaging probes are 
engineered to selectively bind disease state biomarkers that are upregulated on or near 
neoplasms and passively clear from background tissues. Combining ligands with reporter 
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agents such as microbubbles, fluorophores, and radioisotopes and utilizing imaging 
modalities including single-photon emission computed tomography (SPECT), positron 
emission tomography (PET), fluorescence molecular tomography (FMT), and 
ultrasonography the detection, location, classification, and mobility of various cancers can 
be determined.  
A modality with significant potential for molecular imaging is PET. PET contrast 
agents are created through the addition of short half-life positron emitting radionuclides 
such as 68Ga (𝑡1
2⁄
~ 1.1 h), 18F (~ 1.8 h), and 64Cu (~ 12.7 h) with biomarker targeted ligands 
through covalent linkage122 or radiometal chelating moiety123. As the radioisotope 
undergoes positive beta decay a positron is emitted, travelling a short distance124–126 (~ 0.1 
– 1 cm) before annihilating with an electron that causes the simultaneous discharge of two 
opposing γ-rays which are detected by surrounding scintillators. Images are then 
reconstructed from coincidence events. PET benefits from meter scale depth penetration, 
increased sensitivity due to a high level of emitted events, and millimeter length spatial 
resolution. 
Low molecular weight (3 – 20 kDa) proteins and peptides are well-suited as PET 
imaging agents due to favorable pharmacokinetic properties, low immunogenicity, and 
rapid evolvability towards target binding through directed evolution. Small size enhances 
vascular extravasation through fenestrations between endothelial cells common to 
abnormally constructed tumor vessels, increasing tumor penetration and localization. 
Additionally, with molecular weights below the cutoff for glomerular filtration they are 
removed from the plasma rapidly, preventing deleterious background signal.127 These 
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coupled effects provide an early time point imaging contrast not possible with larger 
molecules or traditional imaging modalities.128–130  
Borrowing from the structural efficacy of the antibody and combining a stabilizing, 
core framework and secondary structure with diversifiable, affinity regions, several small 
protein ‘alternative scaffolds’ have been discovered and evolved as ligands towards 
numerous relevant biomarkers including vascular endothelial growth factor (VEGF), 
vascular endothelial growth factor receptor 2 (VEGFR-2), human epidermal growth factor 
receptor 2 (HER2), interleukin-6 (IL-6), and tyrosine-protein kinase Met (c-MET).131,132 
1.5. Affibody and Gp2 scaffolds are promising biomarker imaging agents 
Two compelling small proteins with potential as PET imaging agents for cancers 
that overexpress EGFR are the affibody and Gp2 scaffolds. 
 
Figure 1-1. Solution structures of affibody and Gp2 scaffolds (A) ABY-025 affibody 
and (B) wild-type Gp2 scaffolds with acidic (blue), basic (red), and paratope (green) 
residues highlighted [PDB: 1H0T133 and 2WNM134]  
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The affibody is a 58-residue (~ 6.5 kDa), naturally cysteine-free, three anti-parallel 
α-helical-bundle based on the Z domain, a thermally stabilized, reversible and rapidly 
refolding135, and highly soluble variant of the B domain from staphylococcal protein A136. 
Thirteen surface-exposed residues on the first and second helices, naturally selected to bind 
the Fc region of immunoglobulin G, have been mutated through directed evolution towards 
a myriad of targets for imaging, therapeutic, and biotechnological purposes.137 Affibody 
ligands for molecular targets of clinical concern have been explored extensively, resulting 
in low nanomolar to picomolar binders against TNF-α, EGFR, HER3, VEGF, VEGFR-2, 
IGF-1R, and IL-6.138 As a rapidly evolving medical technology, many affibodies remain in 
vitro or preclinically evaluated, but clinical studies have been performed with 68Ga- and 
111In-labeled anti-HER2 ABY-025 affibody139–141 and molecular imaging studies of EGFR 
and IGF-1R with affibodies are ongoing142,143. 
Substantial effort to improve the affibody framework was undertaken by 
Feldwisch, et. al. in the context of an HER2-binding affibody, ZHER2:342.
144 Primary 
considerations for an optimized framework included an increase in thermal stability and 
hydrophilicity, reduction of immunoglobulin affinity, and amenability for solid-phase 
peptide synthesis while retaining target binding. Site-directed mutagenesis of 11 
framework positions provided a 4 ºC melting point (Tm) increase, reduced immunoglobin 
interaction, and enhanced hydrophilicity with negligible effects on HER2 affinity (ABY-
025). Mutational benefits were often mutually exclusive. N23T raised the Tm by 6 ºC, but 
this elevated stability was eradicated at the expense of increased hydrophilicity from A42S, 
A46S, and A54S. Mutations in ABY-025 increased the affibody framework charge state 
from +5/-7 to +6/-8, making acidic and basic residues 31% of the ligand backbone. Amino 
14 
 
acid based ‘N3S’ radiometal chelators have also been added to
145 or incorporated into146 
the affibody’s N- and C-termini to modulate biodistribution with resultant reductions in 
gastrointestinal tract and excretory organs retention. Finally, in an effort to improve the 
affibody’s tumor-to-background uptake ratio the third, nonbinding helix was removed 
completely with a concurrent addition of stabilizing cysteines for disulfide bridge 
formation.147 Unfortunately, the resultant two-helical construct underperformed in vivo 
with a reduction in tumor uptake and increase in background signal suggesting the third-
helix requisite for effective tumor targeting.148 Given its highly charged framework, utility 
in medical and biotechnological applications, and initial structural stability, the affibody is 
a suitable protein with which to evaluate the impact of ionic charge mutations on 
physicochemical properties and in vivo ligand performance. 
Gp2 is a 45-residue domain (~ 5.5 kDa) based on a dual-termini truncated version 
of the T7 phage gene 2 protein, an E. coli RNA polymerase inhibitor. It contains an α-helix 
opposing three β-strands with two flexible, solvent exposed loops typically diversified for 
epitope binding.149 Gp2 ligands with low nanomolar affinity have been developed for 
model targets such as goat IgG, rabbit IgG, and lysozyme as well as clinically relevant 
markers including EGFR149, insulin receptor150, and PD-L1 (Kruziki, Sarma, and Hackel, 
under revision).  
Framework mutations outside the paratope of Gp2 have resulted from error-prone 
PCR during directed evolution149 or selected degeneracy applied at naïve library creation 
(Kruziki, Sarma, and Hackel, under revision). Positions 30, 31, and 32 shifted away from 
wild-type amino acids during rounds of PCR mutagenesis between target sorts, suggesting 
a region of mutational flexibility. Lead goat and rabbit IgG-binding clones retained several 
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of these residue replacements (E30V, Q32R and E30F, W31G) and demonstrated a 
concurrent ΔTm of +3 or +13 ºC, respectively. Site-selective degeneracy in the Gp2 
framework at three charged positions (E20, E27, and R44) revealed a preference for 
retaining wild-type charge residues over neutral amino acids. 
Gp2 has segregated patches of acidic and basic residues on the α-helix and first and 
third β-strands respectively. These regions may drive nonspecific binding73, increase off-
target retention38,79,80, and lower recoverable production yield due to decreased 
solubility151–153. Additionally, R42 and R44 are required for Gp2’s natural function, E. coli 
RNA polymerase inhibition.134 Therefore, arginine at these positions may be suboptimal 
for prokaryotic production and warrant replacement. As an alternative scaffold with 
demonstrable evolvability towards numerous cancer biomarkers and clinical potential as a 
noninvasive disease state imaging probe, an experimental evaluation of the effects surface 
charge reduction and redistribution have on the robustness and in vivo performance of the 
Gp2 scaffold are merited. 
In the work described herein, we have used rational and semi-rational design in 
concert with combinatorial library selection to engineer the ionic charge of affibody and 
Gp2 scaffolds. The effect of charge on physicochemical properties and in vivo performance 
was evaluated in the context of anti-EGFR ligands bearing varied net, total, and distributive 
charge. Results aid future protein charge modulation and advance the therapeutic, 




Chapter 2 - Synthetic and natural consensus design for 
engineering charge within an affibody targeting epidermal 
growth factor receptor 
2.1. Outline 
Protein ligand charge can impact physiological delivery with charge reduction often 
benefiting performance. Yet neutralizing mutations can be detrimental to protein function. 
Herein, three approaches are evaluated to introduce charged-to-neutral mutations of three 
cations and three anions within an affibody engineered to bind epidermal growth factor 
receptor. These approaches – combinatorial library sorting or consensus design, based on 
natural homologs or library-sorted mutants – are used to identify mutations with favorable 
affinity, stability, and recombinant yield. Consensus design, based on 942 affibody 
homologs, yielded a mutant of modest function (Kd = 11 ± 4 nM, Tm = 62 ºC, and yield = 
4.0 ± 0.8 mg/L as compared to 5.3 ± 1.7 nM, 71 ºC, and 3.5 ± 0.3 mg/L for the parental 
affibody). Extension of consensus design to ten additional mutants exhibited varied 
performance including a substantially improved mutant (Kd = 6.9 ± 1.4 nM, Tm = 71 ºC, 
and 12.7 ± 0.9 mg/L yield). Sorting a homolog-based combinatorial library of 7 x 105 
mutants generated a distribution of mutants with lower stability and yield but did identify 
one strongly binding variant (Kd = 1.2 ± 0.3 nM, Tm = 69 ºC, and 6.0 ± 0.4 mg/L yield). 
Synthetic consensus design, based on the amino acid distribution in functional library 
mutants, yielded higher affinities (p = 0.05) with comparable stabilities and yields. The 
best of four analyzed clones had Kd = 1.7 ± 0.5 nM, Tm = 68 ºC, and 7.0 ± 0.5 mg/L yield. 
While all three approaches were effective in creating targeted affibodies with six charged-
to-neutral mutations, synthetic consensus design proved to be the most robust. Synthetic 
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consensus design provides a valuable tool for ligand engineering, particularly in the context 
of charge manipulation. 
2.2. Introduction 
Ligand charge impacts in vivo performance, particularly physiological distribution. 
Cationic and highly anionic polypeptides clear the blood more rapidly than their neutral 
counterparts.154 Additionally, positively charged proteins have increased vascular 
permeability and extravasate more rapidly in solid tumors.75 Escalation in the number of 
positively or negatively charged residues increases kidney signal at early time points for 
multiple ligands.80,82,155 In particular, reduction in the number of charged residues has been 
effective to improve biodistribution for several scaffolds including the affibody80,155, 
knottin79, and fibronectin type III domain38. Thus, charge modulation – in particular, 
reduction – warrants further investigation for improved ligand delivery. 
Yet charge modification can significantly impact protein solubility, stability, 
affinity, specificity, and production. Introducing charged residues on the surface of a 
protein is generally well-tolerated and in some cases beneficial to stability and solubility.90 
However, removal of charged residues can be more problematic.38,90 Numerous systems 
have exhibited reduced solubility upon charged-to-neutral residue replacements: two 
independent mutations (E48N or D130N) in type S1 dihydrofolate reductase156, a 
combination of five neutralizing mutations in the KcsA potassium channel151, K185F 
mutation in HIV integrase152, K435L mutation in viral reverse transcriptase157, and E100W 
mutation in leptin153. Some previous efforts to modify charge for pharmacokinetic impact 
studied large molecules, such as antibody Fc71,158 in which a few amino acid mutations are 
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less likely to affect protein properties. Conversely, a similar number of charge mutations 
within a small ligand represents a greater fraction of the total protein and may therefore be 
more impactful.  
The current study evaluates three different protein engineering approaches to 
modulate charge of the affibody domain. Affibodies are 58-residue, three-helix bundles 
based on the B domain of staphylococcal protein A.136 Directed evolution of 13 residues 
on the surface of two helices has yielded molecular targeting agents for imaging and 
therapy, as well as scientific reagents.159 Several affibodies have been engineered to bind 
selectively to epidermal growth factor receptor (EGFR) including ZEGFR:1907, with 3 nM 
affinity160. EGFR is overexpressed in numerous cancers161 and improved affinity ligands 
could have utility in molecular imaging and targeted therapy. The presented analyses were 
performed in the context of a hybrid affibody with the 13 paratope mutations of ZEGFR:1907 
and framework mutations engineered, in the context of ZHER2:342
144, for improved synthesis 
and stability while maintaining binding affinity but without direct consideration of charge. 
The use of natural homolog sequences to predict mutational tolerance has been 
useful162–164, albeit inconsistent165,166, for general mutations. We aimed to study the ability 
of homolog sequences to predict tolerance of charged-to-neutral mutations. Yet, consensus 
design is limited by the ability of nature to sample sequence space as well as the requisite 
retention of functional activity, which is different than our current activity of interest, i.e., 
EGFR binding. Thus, considering the potential limitations of consensus design, we allowed 
homolog sequences to guide our selection of mutations while extending beyond natural 
consensus design. High throughput sorting of a combinatorial library – using the genotype-
phenotype linkage of yeast display167 and flow cytometry – expands the number of mutants 
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that can be efficiently evaluated albeit with potential limitations on the characterization of 
some phenotypes. The two approaches can be combined to overcome the limitations of 
natural consensus design. High throughput sorting can efficiently identify a population of 
functional sequences to serve as a synthetic basis for consensus design, which has been 
effectively implemented in evolving the chorismate mutase enzyme.168 
Herein, these three approaches – consensus design, combinatorial library screening, 
and synthetic consensus design – were used to introduce numerous variations of six 
simultaneous charged-to-neutral mutations within an EGFR-binding affibody. Mutant 
analysis at the clonal and population levels provides significant insight into the impact of 
charged-to-neutral mutations within this affibody domain. While all three approaches 
yielded a range of affinities, stabilities, and recombinant yields including several highly 
functional mutants, synthetic consensus design was the most effective. A mutant with 3.2 
± 1.9-fold enhanced affinity (1.7 ± 0.5 nM Kd), comparable stability (68 ºC Tm), and 
improved yield (7.0 ± 0.5 mg/L), despite neutralization of six charged residues, was 
engineered. 
2.3. Materials and Methods 
2.3.1 Pfam Homolog Consensus 
Affibody EA68 (Figure 2-1, origin described in Results) was used as the seed 
sequence in a search of the Pfam database.169 Proteins with less than 42 residues were 
discarded resulting in 942 homologs. Sequences were aligned to EA68 using a block 
substitution (BLOSUM) scoring matrix.170 Amino acid frequencies were calculated at each 
site with a modification to account for repeat sequences without allowing their redundancy 
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to dominate sequence statistics: identical sequences were counted as the square root of the 
number of occurrences of the sequence. 
2.3.2 Clone Production and Yield Quantification 
Genes were constructed by overlap extension PCR171 of eight oligonucleotides 
(Integrated DNA Technologies) per clone, digested by NheI-HF and BamHI-HF restriction 
enzymes (New England Biolabs), and ligated into a pET-22b vector containing a C-
terminal hepta-histidine (Novagen, EMD Millipore) with T4 DNA ligase (New England 
Biolabs). Plasmids were transformed via heat-shock into high efficiency T7 E. coli (New 
England Biolabs), and proper transformants were selected on lysogeny broth (10 g/L 
tryptone, 5.0 g/L yeast extract, 10.0 g/L sodium chloride in water) plates (15 g/L agar) 
containing kanamycin (50 mg/L). Two mL of saturated culture was added to 100 mL of 
lysogeny broth medium in a 250 mL shake flask, incubated at 37 °C, 250 rpm until an 
optical density at 600 nm between 0.5 and 1 units was achieved and induced with 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside for 2 hours at 25 – 28 °C. Cells were pelleted, 
resuspended in lysis buffer (50 mM sodium phosphate (pH 8.0), 0.5 M sodium chloride, 
5% glycerol, 5 mM 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate, and 
25 mM imidazole), and underwent four freeze-thaw cycles. The soluble fraction was 
isolated from cell lysate via centrifugation at 12,000g for 10 min. Affibodies were purified 
by immobilized metal affinity chromatography on 0.2 mL resin volume Ni-NTA HisPur 
spin columns (Thermo Fisher Scientific) and concentration assessed using absorbance at 
280 nm on a Synergy H1 microplate reader (BioTek). Clones were further purified by 
reversed-phase high-performance liquid chromatography with a C18 column using a 15-
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minute gradient of 25% to 80% elution buffer (90% acetonitrile, 9.9% water, 0.1% 
trifluoroacetic acid) and the remaining solution composed of running buffer (99.9% water, 
0.1% trifluoroacetic acid). Isolated affibodies were lyophilized. Yields are presented as the 
average ± standard error of eight or nine production runs. 
2.3.3 Library Construction and Sorting 
Genes for four charge-reduced affibody sub-libraries were constructed via overlap 
extension PCR of 12-15 oligonucleotides per sub-library, with degenerate codons present 
at six of the following positions: 2, 4, 7, 8, 15, 37, 49, 53, or 58 (Table 2-1). 
Table 2-1. Oligonucleotides used to create EA35 sub-libraries.  
 
PCR reaction products and linearized pCT surface display vector were 
homologously recombined upon transformation via electroporation into EBY100 yeast.172 
Transformants were allowed to multiply in SD-CAA (0.07 M sodium citrate (pH 5.3), 6.7 
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g/L yeast nitrogen base, 5 g/L casamino acids, and 20 g/L glucose in water) at 30 °C, 250 
rpm until log phase growth, then pelleted and resuspended in SG-CAA (0.1M sodium 
phosphate (pH 6.0), 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 19 g/L galactose, 
and 1 g/L glucose in water) and shaken at 30 °C, 250 rpm for 8-24 h to induce cell surface 
affibody expression. Libraries were then pooled for fluorescence-activated cell sorting 
experiments. Two populations of 6.7 x 106 (10x theoretical diversity) cells were pelleted, 
washed with 4 °C PBS containing 1% bovine serum albumin (PBSA), and heated to 70 °C 
for 30 min. Cells were kept at 4 °C from this point forward. The yeast were then washed 
with cold PBSA, pelleted, and resuspended in PBSA with 20 mg/L mouse anti-c-MYC 
antibody (clone 9E10, Covance) with or without 20 nM biotinylated EGFR ectodomain 
(Prospec). After incubating on ice for 10 min, the populations were washed, pelleted, and 
resuspended in PBSA, streptavidin-Alexa Fluor 647 (Life Technologies), and goat anti-
mouse-FITC antibody (Sigma-Aldrich). Yeast were sorted on a FACSAria II (BD 
Biosciences) flow cytometer with the top 5% of cells, in terms of EGFR binding : surface 
expression ratio, collected. Plasmids from collected yeast were recovered with a Zymoprep 
kit (Zymo Research) following manufacturer’s protocol and affibody-encoding genes 
amplified by PCR. Resultant PCR products were homologously recombined with pCT 
vector upon electroporation into EBY100 yeast. Two additional sorts were performed 
following this procedure, with the exception that in those cases cells were heat-treated at 
80 °C rather than 70 °C. Encoding regions from recovered yeast from the final sort were 
PCR amplified, ligated into pET-22b vector, transformed into high efficiency 5-alpha E. 
coli (New England Biolabs) and grown on plates (lysogeny broth with 15 g/L agar and 50 
mg/L kanamycin). Genes from fifty-four plate colonies were sequenced and found to all 
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encode for affibodies. Sixteen sequences had combinations of charge mutations not 
designed into the sub-libraries – in some cases more neutralizations and in other cases less 
– and were discarded. The remaining thirty-eight sequences were used to create synthetic 
consensus frequencies. 
2.3.4 Circular Dichroism 
Purified, lyophilized affibody clones were resuspended in PBS to a concentration 
of 0.5 - 1 g/L. Ellipticity was measured between 200 and 260 nm wavelengths at room 
temperature on a Jasco J-815 spectrophotometer in a quartz cuvette with 1 mm path length. 
Thermal denaturation was performed by measuring ellipticity at 220 nm from 20 to 98 °C 
(2 °C/min). The midpoint of thermal denaturation (Tm) was calculated using a two-state 
unfolding model. Heated samples were cooled to 20 ºC and subjected to a post-heating 
wavelength scan. 
2.3.5 Affinity Measurement 
A431 epidermoid carcinoma cells, which express approximately 2.8 x 106 EGFR 
per cell173, were provided by Dr. Daniel Vallera (University of Minnesota). Cells were 
cultured in high-glucose Dulbecco’s modified Eagle’s medium with 10% fetal bovine 
serum and 1% penicillin streptomycin at 37 °C in humidified air with 5% CO2. At 70-80% 
confluence, cells were detached with trypsin-ethylenediaminetetraacetic acid, pelleted, and 
resuspended in cold PBSA to prevent EGFR internalization prior to use. Fifty thousand 
cells were washed with PBSA and incubated with varying concentrations of ligand. Cells 
were pelleted, washed again with PBSA, and incubated with fluorescein-conjugated anti-
His6 antibody (Abcam) in PBSA. Cells were washed and analyzed using flow cytometry 
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on an Accuri C6 (BD Biosciences). Median fluorescence values at each ligand 
concentration, corresponding to binding fraction, were used to determine affinity values 
with least squares regression assuming a 1:1 binding interaction. Equilibrium dissociation 
constants, Kd, are presented as the average ± standard error of three to five titrations. 
2.3.6 Size Exclusion Chromatography and Target Specificity Assay 
Purified and lyophilized affibody clones, aprotinin, and cytochrome C were 
resuspended in PBS to a concentration of 1 mg/mL. 200 uL of each sample was run through 
a Superdex75 10/300 GL size exclusion column on an ӒKTAprime Plus chromatography 
system (GE Healthcare Life Sciences) at a flow rate of 0.5 mL/min for 1 hour. Retention 
volumes were determined by monitoring light absorbance at 280 nm. 
MCF-7 breast adenocarcinoma cells which express fewer than 5 x 103 EGFR per 
cell, graciously provided by Dr. Deepali Sachdev (University of Minnesota), were used as 
pseudo-negative controls for target specificity assays. MCF-7 cells were cultured, 
detached, and processed identically to A431. After detachment and PBSA washing, fifty 
thousand A431 or MCF-7 cells were incubated with 500 nM affibody ligand. Upon binding 
equilibrium, cells were pelleted, washed with PBSA and incubated with fluorescein-
conjugated anti-His6 antibody is PBSA. Cells were pelleted, washed in PBSA again then 
analyzed via flow cytometry on an Accuri C6. Median fluorescence with background signal 
subtracted are presented as the mean ± standard error of three replicates.  
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2.4. Results  
2.4.1 Hybridizing EGFR Targeting Mutations with an Improved Framework  
Affibody ZEGFR:1907 engineered by Friedman et al.
160 to target EGFR was the partial 
basis for our starting ligand. Seven framework mutations, V1A, D2E, N3A, F5Y, N6A, 
N23T, and S33A, identified by Feldwisch et al.144 in the context of a HER2 targeting 
affibody ZHER2:342, were implemented to improve stability and reduce immunoglobulin 
binding (Figure 2-1).  
 
Figure 2-1. Affibody domain solution structure and affibody variant sequences used to 
create clone EA68 (A) Schematic of affibody domain variant (PDB: 1H0T133). (B) 
ZHER2:342174 is an evolved HER2 binder with the original framework sequence. 
ABY-025144 is a mutant with an optimized framework. ZEGFR:1907160 is a mutant with 
13 sites evolved to bind EGFR. EA68 is a combined mutant with the EGFR binding 
mutations and the optimized framework, with five exceptions: three A to S mutants 
– at sites 42, 46, and 54 – were retained as A. These mutations were selected for protein 
synthesis but slightly destabilize the protein; the S33K mutation was avoided because 
of the introduction of charged K and S33A was chosen, which provides 10 ºC with no 
impact on HER2 affinity and reduced Ig binding; the N43E mutation was avoided 
because of the introduction of charged E. Negatively and positively charged residues 
are colored in blue and red, respectively, in the sequence. The corresponding sites in 
the structure are also colored but note that the structure does not correspond to this 
amino acid sequence, but rather a different variant. 
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There are five exceptions from the optimized framework as published: three A to S 
mutants – at sites 42, 46, and 54 – were retained as alanine. These mutations were selected 
to improve protein synthesis at the expense of a slight reduction in stability; the S33K and 
N43E mutations were avoided because of the introduction of charged groups; S33A was 
chosen to provide stabilization (Tm increases 10 ºC) with no impact on HER2 affinity and 
reduced Ig binding. This hybrid molecule, termed EA68 for EGFR-targeting affibody with 
six positively charged residues and eight negatively charged residues, was the basis for our 
protein engineering efforts. EA68 exhibits binding affinity to EGFR-overexpressing A431 
cells with Kd = 5.3 ±1.7 nM (Figure 2-2A), which is comparable to ZEGFR:1907 (2.8 nM). 
The molecule exhibits the expected -helical secondary structure (Figure 2-2B). The 
midpoint of thermal denaturation is 71 ºC (Figure 2-2C), which is comparable to the HER2 
binding affibody with a similarly optimized framework (Tm = 69 ºC) but different sequence 
in the binding paratope. Unfolding is only partially reversible as -helical secondary 
structure, but varied signal, is observed upon cooling to 25 ºC after thermal denaturation 
(Figure 2-2B). The recombinant yield from E. coli is 3.5 ± 0.3 mg/L in unoptimized shake 






Figure 2-2. Characterization of EA68 affibody. (A) A431 cells overexpressing EGFR 
were incubated on ice with the indicated concentration of purified EA68 followed by 
fluorescein-conjugated anti-His6 antibody and analyzed by flow cytometry. The 
equilibrium dissociation constant (Kd) is calculated by minimizing sum of squared 
errors between experiment and a theoretical 1:1 binding model. (B,C) Purified EA68 
was analyzed by circular dichroism spectroscopy by (B) scanning wavelengths from 
200 to 260 nm at 20 ºC. Triplicate scans were collected before and after thermal 
denaturation and cooling and (C) scanning temperatures from 20 ºC to 98 ºC (2 
ºC/min.) at 220 nm. The midpoint of thermal denaturation was calculated from a two-
state model. 
2.4.2 Charge Removal by Consensus Design  
A consensus design approach was implemented to identify tolerable mutations to 
remove charged residues. Natural homologs to the engineered affibody were identified 
from the Pfam169 database using EA68 as the basis sequence. Amino acid frequencies were 
calculated at each site based on the 942 homologs in the family. Identical sequences were 
partially discounted to account for their multiple natural appearances without allowing their 
redundancy to dominate sequence statistics. The charged framework sites exhibit variable 
conservation with a frequency range of 5 - 92%, median of 64%, and standard deviation of 
30% (Table 2-2). Frequencies of neutral residues range from 2% to 72%. The median 
number of different amino acids observed at each charged site was 6.5. The median 
Shannon entropy175 was 1.2 for all sites and 1.4 at charged framework sites. These values 
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indicate a modest level of diversity from which to design mutants. Three positive and three 
negative residues were mutated to neutral within the framework of EA68. Consensus 
design identified the set of six charged-to-neutral mutations whose summed natural 
frequencies were highest: E2Q (24%), K4N (38%), E8A (21%), E15Q (30%), K49Q 
(21%), and K58N (62%). A clone incorporating all six mutations, named EA35, exhibited 
a comparable affinity (11 ± 4 nM) and recombinant yield (4.0 ± 0.8 mg/L) to EA68 but a 




Table 2-2. Natural amino acid frequencies at each charged site (excluding sites 14 and 
17 engineered for binding). Amino acids for clone EA68 and the mutant that removes 
three acidic and three basic residues while maximizing natural neutral frequency 
(Max Neutral, also known as EA35) are reported. The amino acids of mutants are 
noted with matches to EA35 indicated as •. 
 
An additional ten mutants, similarly selected based on summed natural amino acid 
frequencies, were produced and evaluated (Figure 2-3). Overall, all but one mutant (EA35 
A8Q) had affinities within 3-fold of EA68 (range: 6.9 ± 1.4 nM to 20 ± 7 nM versus 5.3 ± 
1.7 nM). All recombinant yields were comparable or better than EA68 (range: 4.0 ± 0.8 
mg/L to 16.6 ± 0.8 mg/L versus 3.5 ± 0.3 mg/L). However, 9 of 11 thermal stabilities 
decreased by at least 5 ºC (range: 59 ºC to 71 ºC versus 71 ºC). The reversibility of 
unfolding varies between mutants in regards to secondary structure as assessed by circular 
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dichroism spectroscopy (Figure 2-4). The optimal combination of affinity and stability is 
EA35 A8E/D37N: 6.9 ± 1.4 nM affinity and 71 ºC Tm, which had the fifth highest sum of 
natural frequencies. 
 
Thermal stability (black diamonds), affinity (gray circles), and recombinant yield 
(white squares) for EA68, EA35, and EA35 variants. The midpoints of thermal 
denaturation (Tm) were measured by circular dichroism spectroscopy of purified 
protein (n = 1 - 2 with a mean difference of 7%). The equilibrium dissociation 
constants were measured by titration of affibody mutants on A431 cells using flow 
cytometry to detect binding (n = 3 - 5). Recombinant yield is the amount of 
purified affibody recovered per L of culture (n = 8 - 9). Points and error bars 




Figure 2-4. Circular dichroism spectroscopy of mutants. Purified affibody domains 
were analyzed by circular dichroism spectroscopy by scanning wavelengths from 200 
to 260 nm. Triplicate scans were collected before (- - -) and after (–––) thermal 
denaturation and cooling. 
Several sets of mutants differ by the choice of neutral amino acid at a single site, 
which enables sitewise analysis of amino acid choices at sites 2, 4, 8, and 15 (Figure 2-3 
and Figure 2-5). At site 2, A, N, and Q yield indistinguishable affinities while Q2A 
provides modestly elevated stability. At site 4, N, Q, and S yield similar affinities and 
stabilities; N4Q and N4S provide elevated yields. At site 8, A8N provides the optimal 
affinity whereas A8Q provides the highest stability; A8Q and A8N provide elevated yields. 
Q and V, at site 15, provide similar affinities, stabilities, and yields. Moreover, three 
mutants have a charge reversion relative to EA35 as well as a neutralizing mutation (i.e. 
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A8E/D53S, K7A/Q49K, and A8E/D37N) which required the production and analysis of 
five additional mutants to allow for individual site comparisons (Figure 2-3 and Figure 2-
5). EA35 K7A/Q49K maintains affinity and stability with high yield. Analysis of the 
individual mutations to EA35 revealed that both EA35 K7A and EA35 Q49K had improved 
affinity, moderate stability, and high yield. EA35 A8E/D53S has modest affinity but 
improved stability and yield. Single mutant EA35 A8E had high affinity and stability and 
reasonable recombinant yield while EA385 D53S bound with 6.4 ± 2.9 nM affinity but was 
less stable. While EA35 A8E/D37N was the most stable EA35 mutant (Tm = 71 ºC), EA35 
A8E was only slightly more stable than EA35 (65 ºC) and EA35 D37N was less stable (58 
ºC). The synergy of these mutations is reasonable given their proximity (11.2 Å, on 
average, in affibody variants with solved structures.). Yet binding and yield lack these 
synergies as EA35 A8E provides the strongest binding (2.8 ± 1.0 nM) while EA35 D37N 





Figure 2-5. Sitewise comparisons from Figure 2-3. The midpoints of thermal 
denaturation (Tm, diamonds) were measured by circular dichroism spectroscopy of 
purified protein (n = 1 - 2 with reproducibility of 7%). The equilibrium dissociation 
constants (circles) were measured by titration of affibody mutants on A431 cells using 
flow cytometry to detect binding (n = 3 - 5). Recombinant yield (squares) is the 
amount of purified affibody recovered per L of culture (n = 8 - 9). Points and error 
bars represent means and standard deviations. 
The properties of the collection of consensus mutants were analyzed to assess the 
utility of natural sequence frequency to guide mutational design. No significant correlation 
was observed between performance (affinity, stability, or yield) and natural sequence 
frequency as assessed by the change in natural frequency between pairwise mutants (Figure 




Figure 2-6. Relationships between performance (affinity, stability, and yield) and amino 
acid frequency in natural homologs. (A-C) For sets of mutants differing at a single site, 
the affinity (A), thermal stability (B), and recombinant yield (C) are plotted against 
the change in natural frequency of the amino acids at the site of interest. (D-F) For 
EA35 and its equally charged mutants, the affinity (D), thermal stability (E), and 
recombinant yield (F) are plotted against the normalized sum of natural frequencies 
at the six sites mutated relative to EA68. p > 0.05 for all plotted relationships. 
2.4.3 Charge Removal in a Combinatorial Library  
Based on the variability of consensus design for EA68 and other molecules165,166, a 
parallel approach was used that expanded the evaluated sequence space. Combinatorial 
libraries were created in which three positively charged sites and three negatively charged 
sites were mutated to neutral amino acids (Table 2-3). The six mutated sites were chosen 
again based on natural homolog sequence frequencies, but now using cumulative neutral 
residue frequency as the metric. Thus, the first library design diversified E2, E8, and E15 
(56%, 37%, and 42% neutral naturally) while conserving D36, D37, E47, and D53 (2%, 
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22%, 7%, 18% neutral naturally); analogously, K4, K7, and K58 (59%, 33%, and 72% 
neutral) were diversified while K49 and K50 (25% and 10%) were conserved. Three 
variations were also considered in which an alternative site was diversified and, 
concomitantly to retain the same overall charge, a previously diversified site was conserved 
as charged: (Library 1) K49 was diversified and K7 conserved; (Library 2) D37 was 
diversified and E8 conserved; or (Library 3) D53 diversified and E8 conserved. The 
permitted neutral residues were chosen as degenerate codons that incorporated the naturally 
frequent amino acids while also permitting additional chemical functionalities yet 
excluding charged residues. Five to nine amino acids were permitted at each site to yield 
theoretical diversities of ≤ 2 x 105 mutants. The four libraries were constructed within a 
yeast surface display system with 2.1 x 107 to 3.4 x 107 transformants per library, yielding 
> 99% sampling of theoretical sequence space.176 
Table 2-3. Amino acid diversities allowed in the four sublibraries for selection of 
EA68 mutants with removal of three acidic and three basic residues.  
 
The combinatorial libraries were pooled and sorted for stability and binding affinity 
by thermally treating the yeast-displayed proteins at 70 - 80 ºC and, after cooling, testing 
binding to 20 nM EGFR ectodomain. Note that thermal denaturation of EA35 and its 
variants is not fully reversible in the yeast displayed context, which enables this thermal 
stress to be effectively used (Figure 2-7A). Mutants exhibiting the best retention of thermal 
stability and binding were collected and sequenced. Sitewise amino acid frequencies 
(Figure 2-7B,C) exhibit a range of behaviors. Amino acids dominant in stable binders are 
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frequent in natural homologs although the inverse is not always true. For example, site 58 
is 86% N when naturally neutral, but only 5% N in synthetically sorted mutants. No 
synthetically dominant residue is rare naturally, although several residues absent naturally 
are observed at reasonable percentages in sorted binders (maximum: 27% and median: 4% 
for amino acids not observed in natural homologs). 
 
Figure 2-7. Combinatorial library analysis. (A) Yeast displaying affibodies (left: 
parental EA68, right: enriched stable binding mutants) were treated at 20 ºC or 80 
ºC for 30 min, cooled, and incubated with 20 nM biotinylated EGFR ectodomain. 
Binding was detected by streptavidin-AlexaFluor 647, and affibody display was 
quantified with anti-c-myc antibody with anti-mouse-AlexaFluor 488 using flow 
cytometry for quantification. (B) Amino acid frequencies at each diversified site in 
the combinatorial libraries and enriched stable binders. (C) The observed sequence 
frequencies in the stable binders relative to the amino acid frequencies in natural 
affibody homologs. Squares represent K7 and K49 for which the synthetic sequence 
frequencies sum to, at most, 100% because of the library design requirement to 
maintain three cations. Circles indicate E8, D37, and D53 for which the synthetic 
sequence frequencies sum to, at most, 200%. 
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Four mutants from the sorted population were produced recombinantly and evaluated for 
yield, affinity, stability, and secondary structure (Figure 2-8). Three of the four clones have 
thermal stabilities lower than any of the consensus designed mutants (Figure 2-9). The 
average Tm of mutants selected from the library is 57 ± 4 ºC versus 64 ± 1 ºC for consensus 
designed mutants (p = 0.23 for two-tailed Student’s t-test). Production yields were slightly 
lower for library mutants (6.7 ± 2.0 mg/L) than consensus mutants (9.8 ± 1.2 mg/L; p = 
0.24). Affinities were similar between groups (12 ± 6 nM for library mutants and 11 ± 1 
nM for consensus mutants). Notably, though, one of the mutants (EA35 
Q2A/K7T/A8E/Q49K/D53Y/N58Y) exhibited very good stability (69 ºC) and affinity (1.2 
± 0.3 nM) with an acceptable yield (6.0 ± 0.4 mg/L). 
 
Figure 2-8. Analysis of clones from combinatorial library and synthetic consensus 
design. The midpoints of thermal denaturation (Tm) were measured by circular 
dichroism spectroscopy of purified protein. The equilibrium dissociation constants 
were measured by titration of affibody mutants on A431 cells using flow cytometry to 
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detect binding (n = 3). Recombinant yield is the amount of purified affibody recovered 
per L of culture (n = 9). Points and error bars represent means and standard error. 
 
Figure 2-9. Relationship between biophysical properties and design strategy. Thermal 
stability (left), affinity (center), and recombinant yield (right) comparison across 
design strategies. 
2.4.4 Consensus Design from a Synthetic Population 
The amino acid frequencies observed in the stable, binding population were used 
as the basis for synthetic consensus design. Such an approach – using a synthetic source of 
diversity for consensus design – was successful for enzyme engineering.168 As in the 
consensus design from natural homolog sequences above, mutants were designed to 
neutralize three negatively charged residues and three positively charged residues with a 
maximal sum of observed frequencies. The top four synthetic consensus designs were 
produced and evaluated (Figure 2-8). Thermal stabilities were comparable to consensus 
design (65 ± 1 ºC versus 64 ± 1 ºC); yields were also similar (11 ± 3 mg/L versus 9.8 ± 1.2 
mg/L). Affinities were significantly improved (p = 0.05) with two improved mutants 
(EA35 N4Y/K7A/A8Q/Q49K/N58Y with Kd = 1.8 ± 0.4 nM and EA35 
N4P/K7P/A8Q/Q49K/N58Y with Kd = 1.7 ± 0.5 nM) and two mutants with affinities 
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similar to natural consensus designs. Notably, EA35 N4P/K7P/A8Q/Q49K/N58Y also has 
strong stability (68 ºC) and acceptable yield (7.0 ± 0.5 mg/L). 
2.4.5 Cellular Binding Specificity, Protein Oligomerization and Solubility 
To address the possibility of nonspecific binding, A431 (~3 million EGFR per cell) 
and MCF-7 (< 5,000 EGFR per cell) cell lines were incubated with EA68 and six 
representative charge-reduced clones at 500 nM and analyzed using flow cytometry (Figure 
2-10).  For all clones tested, median fluorescence of MCF-7 samples were not statistically 
different from those containing 0 nM ligand (p = 0.15). Additionally, at 500 nM ligand, 
fluorescent signal was 2 - 3 orders of magnitude higher for A431 cells than MCF-7 in all 
cases. 
 
Figure 2-10. Cellular EGFR binding specificity. MCF7 (EGFR-) and A431 (EGFR+) 
cell lines were incubated on ice with 500 nM affibody ligand, labeled with fluorescein-
conjugated anti-His6 antibody, and median fluorescence determined by flow 
cytometry (n = 3). Bars and error bars represent means and standard error. 
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EA68 and seven EA35 affibodies were analyzed with size exclusion 
chromatography to assess their degree of oligomerization (Figure 2-11). Aprotinin (6.5 
kDa) and cytochrome c (12.3 kDa), used as standards, eluted in 15.9 and 13.9 mL retention 
volumes respectively. EA68 eluted closest to aprotinin at 16.2 mL with all EA35 clones 
eluting between 17.0 and 20.1 mL of PBS with an average ± standard deviation of 18.0 ± 
1.1 mL. Modest peak broadening was also observed. For all proteins tested, no aggregation 
was visible up to and including concentrations of 1 mg/mL in PBS. 
 
Figure 2-11. Size exclusion chromatography of mutant subset. Lyophilized proteins 
were resuspended in PBS to 1 mg/mL of which 0.2 mg was passed through a Superdex 
75 30/100 size exclusion column at 0.5 mL/min and elution monitored by absorbance 
at 280 nm. Aprotinin and cytochrome c were used as molecular weight standards. 
2.5. Discussion 
Consensus design was successful in achieving comparable affinity (Kd = 11 ± 4 nM 
for EA35 vs. 5 ± 2 nM for EA68) and recombinant yield (4.0 ± 0.8 mg/L vs. 3.5 ± 0.3 
mg/L) when neutralizing six charged residues from the parental affibody but exhibited 
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significantly reduced thermal stability (Tm = 62 ºC vs. 71 ºC) (Figure 2-3). The results 
reveal that it is valuable to explore various mutants near the consensus design as four of 
the other ten homolog-guided mutants had higher stabilities, three had nominally higher 
affinities (albeit with differences of modest statistical power), and eight of ten mutants had 
higher yields. In particular, EA35 A8E/D37N provides 10 ºC higher thermal stability, 1.6 
± 0.9-fold stronger affinity, and 3.2 ± 0.9-fold increased recombinant yield relative to the 
consensus mutant EA35. In fact, EA35 A8E/D37N is comparable to the original EA68 
despite the neutralization of six charged residues. Thus, while consensus design is a 
validated approach, it does not always yield the optimal solution. Amino acid frequency in 
natural homologs can be useful for identifying tolerated amino acids, but their exact choice 
should not be dictated by the precise natural frequency as evidenced by the lack of 
correlation between performance (affinity, stability, or yield) and natural frequency for the 




Figure 2-12. Relationships between performance (affinity, stability, and yield) and 
amino acid frequency in natural homologs. (A-C) For sets of mutants differing at a 
single site, the affinity (A), thermal stability (B), and recombinant yield (C) are plotted 
against the change in natural frequency of the amino acids at the site of interest. (D-
F) For EA35 and its equally charged mutants, the affinity (D), thermal stability (E), 
and recombinant yield (F) are plotted against the normalized sum of natural 
frequencies at the six sites mutated relative to EA68. p > 0.05 for all plotted 
relationships. 
The analysis of mutants based on homolog frequencies can be broadened using 
combinatorial library selections provided an efficient assay exists. For example, thermal 
stability can be enriched by heating yeast-displayed proteins.177 While cell death occurs in 
response to the thermal stress, structural integrity is sufficiently maintained to allow for 
precise discrimination via fluorescence-activated cell sorting; plasmids can then be 
recovered and amplified by PCR. In addition, affinity selections are straightforward. 
Libraries were synthesized that include 7 x 105 mutants using degenerate codons including 
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amino acids frequent in homologs as well as rare or unrepresented residues. Combinatorial 
library sorting enabled identification of a mutant with higher affinity than the top 11 
consensus mutants (9.2 ± 5.7-fold stronger than EA35) and thermal stability superior to all 
but one variant (7 ºC higher than EA35). Yet the other three selected mutants were 
comparably or less effective than the consensus mutants. The ability of the thermal and 
binding selection pressure to enrich the highly functional mutant from a collection of 
poorly functional mutants (Figure 2-7A) highlights the power of the approach. Yet, the 
inability of the selection to deplete some of the modestly effective clones relative to the 
highly effective clones highlights the limitations of the technique. The selection of 
comparable affinities to the consensus approach is expected given the selection design: 
affibodies were incubated with 20 nM EGFR ectodomain to focus selections on stability 
with retention of good affinity. 
Despite the lack of correlation of performance and amino acid frequency in the 
consensus family of mutants (Figure 2-12), in the combinatorial library selections, highly 
enriched mutations were only observed for naturally frequent mutations (Figure 2-7B) 
thereby indicating no dominant false negatives from consensus design. There were some 
modest false negatives such as E8Q (16% in natural homologs to 43% in selected mutants), 
K58Y (0% naturally to 27% in selected mutants), and eight other mutations absent 
naturally but present at least 10% in selected mutants. As in the direct consensus design of 
the top 11 clones (Figure 2-3), there are significant false positives: K4N (93% naturally to 
24% in selected mutants) and K58N (86% naturally to 5% in selected mutants). 
Beyond identification of a mutant with improved affinity, the combinatorial library 
selection – and subsequent sequence analysis of functional mutants – provides an 
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additional amino acid distribution to guide consensus design. This ‘synthetic consensus 
design’ identified a mutant – from only four tested – with 6 ºC higher thermal stability, 6.4 
± 4.3-fold stronger affinity, and 1.8 ± 0.5-fold higher recombinant yield than EA35. In fact, 
this mutant had higher yield, 3.2 ± 1.9-fold (p = 0.05) higher affinity, and comparable 
stability to parental EA68 despite the neutralization of six charged residues. A second 
mutant also had high affinity (1.8 ± 0.4 nM), and the other two synthetic mutants had 
comparable affinities to the natural consensus series resulting in a set of mutants with 
significantly improved (p = 0.05) affinities relative to natural consensus design (Figure 2-
9). It is noteworthy, that the top clones from the combinatorial library selection and the 
synthetic consensus design had two and three mutations (D53Y/K58Y or K4P/K7P/K58Y), 
respectively, that are rare in natural homologs (0 - 2%). Thus, broadened searches of 
sequence space were needed to identify such mutants. 
This EGFR-binding affibody proved to be amenable to all three modes of 
engineering charge. The optimal mode for engineering other molecules could be dependent 
on the molecule of interest as well as the desired properties of interest, but the results herein 
provide valuable guidance. The synthetic consensus approach proved to be the most 
effective (highest affinities and comparable stabilities to natural consensus, which were 
superior to combinatorial library) albeit with modest additional effort relative to natural 
consensus design. Nevertheless, it is a straightforward approach. Moreover, the synthetic 
consensus approach is highly valuable in instances in which natural homolog data is not 
abundant, such as synthetic proteins, or highly conserved at the sites of interest.168 In cases 
where natural homolog data is abundant and a rapid, efficient engineering approach is 
especially valued, natural consensus design can be effective for engineering charge 
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neutralization. Based on the results with EA68, however, it would be recommended to test 
several mutants of high natural frequency. This is evidenced by the improvement of several 
consensus mutants relative to EA35, in particular EA35 A8E/D37N. 
In all, several mutants were engineered with a reduced number of charged residues 
relative to the parental EA68 while maintaining stability, recombinant yield, and affinity 
(which in some cases was actually improved). Receptor specificity was retained, 
demonstrated by binding comparisons between low (MCF-7) and high (A431) EGFR-
expressing cell lines for a representative subset of clones. All mutants tested exhibited 
preferential binding to A431 cells two to three orders of magnitudes higher than MCF-7 as 
represented by median fluorescence. Size exclusion chromatography indicated that clones 
were monomeric at experimentally relevant concentrations. Retention volumes were higher 
than predicted by molecular weight alone and peaks were broadened somewhat, but these 
results may be due to a generally ‘stickiness’ between affibody and column resin. Taken 
together such results validate these molecules as useful variants to examine the impact of 
charge on physiological distribution. 
On a different note, it is worth highlighting that the initial experiment in this study 
examined the ability to merge an evolved framework and an evolved paratope in the 
affibody domain. A subset of the optimized framework mutations – originally identified in 
the context of a HER2 binding affibody144 – were efficiently integrated with a paratope 
evolved at 13 sites to bind EGFR without detriment to affinity or stability. This, along with 
a similar result observed with a HER3-binding paratope178, suggests a modular capability 
of these particular framework mutations, although paratope- and target-dependent impacts 




We were able to apply a selection of the improved affibody framework mutations 
to an evolved EGFR-binding affibody domain and further mutate the molecule for charged-
to-neutral mutations of six residues. The molecule was relatively robust to charge removal 
yet showed differential retention of stability, affinity, and yield dependent upon the site 
and residue of mutation. A consensus design approach of 11 charge-reduced clones yielded 
decreased affinity (median 2.0-fold Kd increase) and stability (median ΔTm = 9 °C) with 
yields exceeding that of parental affibody (median 2.8-fold higher). A broader search of 
sequence space via a homolog-biased combinatorial library yielded comparable affinities 
(12 ± 6 nM vs. 11 ± 1 nM), lower stabilities (57 ± 4 ºC vs. 64 ± 1 ºC), and recombinant 
yields (6.7 ± 2.0 mg/L vs. 9.8 ± 1.2 mg/L). Consensus design from the sequences evolved 
in the synthetic combinatorial library yielded similar results to the natural consensus design 
with modestly improved affinity (to 1.7 ± 0.5 nM). In all, the three methods of charge 
reduction produced a range of phenotypes including several promising lead molecules with 
strong affinity, stability, and recombinant yield. Moreover, the comparison of charge 
modulation techniques provides valuable insight for future charge engineering. 
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2.8. Supplemental Figures 
 
Figure 2-13. Thermal stability by circular dichroism spectroscopy. Purified affibody 
domains were analyzed by circular dichroism spectroscopy at 220 nm for 





Figure 2-14. Affinity titration of mutants. Purified affibody domains were added to 
EGFR-overexpressing A431 cells at the indicated concentration on ice. Binding was 






Chapter 3 - Evaluation of affibody charge modification 
identified by synthetic consensus design in molecular PET 
imaging of epidermal growth factor receptor 
3.1. Outline 
Tumor overexpression of epidermal growth factor receptor (EGFR) correlates to 
therapeutic response in select patient populations. Thus, molecular positron emission 
tomography (PET) imaging of EGFR could stratify responders versus nonresponders. We 
previously demonstrated effectiveness of a “synthetic consensus” design principle to 
identify six neutralizing mutations within a 58-amino acid EGFR-targeted affibody 
domain. Herein, we extend the approach to identify additional neutralized variants that vary 
net charge from -2 to either -4 or +4 while retaining high affinity (1.6 ± 1.2 nM and 2.5 ± 
0.7 nM), specific binding to EGFR, secondary structure, and stability (Tm = 68 ºC and 59 
ºC). We radiolabeled the resultant collection of five charge variants with 64Cu and 
evaluated PET imaging performance in murine models with subcutaneously xenografted 
EGFRhigh and EGFRlow tumors. All variants exhibited good EGFRhigh tumor imaging as 
early as 1 h, with EA35S (+3/-5) achieving 7.7 ± 1.4 %ID/g tumor at 4 h with 1.5 ± 
0.3%ID/g EGFRlow tumor, 34 ± 5 tumor:muscle and 12 ± 3 tumor:blood ratios. The 
positively charged EA62S mutant (+6/-2) exhibited 2.2-3.3-fold higher liver signal than 
the other variants (p < 0.01). The EA68 variant with higher charge density was more stable 
to human and mouse serum than neutralized variants. In a comparison of radiometal 
chelators, 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) exhibited 
superior physiological specificity to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA). In total, these studies comparatively evaluated a set of EGFR-targeted 
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affibodies varying in net charge and charge density, which revealed functional variations 
that are useful in engineering an ideal probe for translational studies.  
3.2. Introduction  
Small protein scaffolds are evolvable towards high target affinity and molecular 
specificity to create valuable imaging131,179, therapeutic180,181, and diagnostic agents182–184. 
Numerous scaffold characteristics influence ligand efficacy including scaffold structure185, 
hydrophilicity38,186, stability 187,188, and ionic charge38,80,189.  
Ligand charge modulation has yielded significant impacts on physiological 
distribution and retention. Cationic charge has increased renal retention in several cases: 
cystine knots rich in arginine versus serine79, affibodies with more lysines in the chelator80, 
and cationic synthetic polypeptides versus amphoteric and anionic variants154. Other 
experimental results implicate anionic charge in renal retention: cystine knots rich in 
glutamic acid versus serine79, bombesin peptide analogs with increased glutamic acids82, 
and affibodies with increased glutamic acids in the chelator189. Thus, charge manipulation 
impacts renal retention with both cationic and anionic residues implicated. Yet charge 
removal is not systematically sufficient to reduce renal retention. Intermediate charge 
removal was optimal for some fibronectin domain variants38. Comparison of cationic and 
anionic Fab fragments revealed that increased positive charge corresponded to nearly a 2-
fold increase in lung localization whereas elevated negative charge resulted in an almost 
3-fold higher stomach signal84. Cationic charge sped plasma clearance kinetics71 for 
albumin75, IgG158,190, Fab190, and dextran191. Cationic charge improved tumor vascular 
permeability – a key limitation for solid tumor targeting192 – for albumin75, IgG75 and 
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nanoparticles78. Moreover, tumor interstitium is negatively charged76 and there is some 
evidence of selective retention of positively charged entities, including liposomes77, though 
this could hinder molecular selectivity73. In short, ligand charge can be impactful, though 
the relationships between charge density and net ligand charge with off-target uptake and 
physiological performance are not well understood, making a priori predictions difficult 
and necessitating several mutants for evaluation. One interpretation of the data suggests a 
reduction in charge density may aid performance. Yet, it is important to modulate charge 
without diminishing desirable ligand characteristics including high production yield and 
soluble recovery, strong affinity, and thermal stability. However, these charge 
modifications can be particularly difficult in the context of a small ligand38,193 where such 
mutations would encompass a greater portion of the protein’s structure98. 
A ligand that may benefit from charge modification is the affibody scaffold194. 
Affibodies are 58-residue, three-helix bundles based on the B domain of staphylococcal 
protein A133 with 13 sites on helices 1 and 2 commonly diversified for binding. They have 
been used extensively to molecularly target clinically relevant biomarkers such as 
transferrin195, TNF-α196, HER2174, and gp120197 with pM to µM affinities. Affibodies are 
also broadly applicable having been used for molecular imaging198,199, therapy200,201, and 
biotechnology202,203. 
We previously hybridized a known epidermal growth factor receptor (EGFR) 
targeted paratope region (ZEGFR:1907)
160 and an optimized backbone framework containing 
seven mutations which were incorporated to improve stability and reduce immunoglobulin 
binding144. The resultant affibody ligand, EA68, containing 6 positive and 8 negative 
residues, was engineered for charge reduction204. Consensus design from natural 
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homologs162,163,205 and mutation tolerance data generated from high throughput screening 
(i.e. ‘synthetic consensus’ design) were used to neutralize six charged residues on EA68 
creating clones EA35A8E,D37N and Synthetic 2N4P,K7P,A8Q,Q49K,N58Y herein known as ‘EA35C’ 
and ‘EA35S’. Both charge-reduced clones maintained single-digit nanomolar affinity (6.9 
± 1.4 nM, 1.7 ± 0.5 nM), high thermal stability (71 °C, 68 °C), and sufficient recombinant 
yield (12.7 ± 0.9 mg/L, 7.0 ± 0.5 mg/L). 
Epidermal growth factor receptor (EGFR), also known as HER1 or ErbB1, is a 
glycoprotein in the ErbB family206 that has been shown to play a key role in tumor survival, 
growth, and metastasis107. EGFR is overexpressed in several tumor types including head 
and neck, breast, renal, non-small cell lung, colorectal, ovarian, pancreatic, and bladder 
cancers207 making it an important prognostic or predictive biomarker and therapeutic 
target. Surface overexpression and gene copy number are predictors of disease response to 
receptor (cetuximab) and tyrosine kinase (gefitinib) inhibitor therapies in both primary and 
metastatic colorectal cancers110,111,208 as well as non-small-cell lung cancers112,113,209. 
EGFR overexpression alone was associated with poor prognosis for patients with HER2-
positive primary breast cancer and predictive of response to trastuzumab therapy115. 
Notably, these results were independent of EGFR copy number and inapplicable to 
metastatic occurrences. 
Thus, effective molecular imaging of EGFR would provide an unmet clinical need 
and allow for appropriate patient stratification to differentiate responders from 
nonresponders. Multiple molecular probes have been preclinically developed for positron 
emission tomography (PET) of EGFR including small engineered proteins – 
affibodies117,210–213, fibronectin domains38,94, and Gp2214 (and nanobodies for single-photon 
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emission computed tomography116,215) – antibodies216–220, small molecule inhibitors221–224, 
and the native ligand225,226. Further development of such probes, to advance sensitivity and 
selectivity, has potential benefit for EGFR imaging.  
Herein, we extend use of mutant tolerance data to explore further charge 
modulation of EGFR-targeted affibody domains. We evaluate the set of mutants – varied 
in net charge and charge density – for PET molecular imaging of epidermal growth factor 
receptor in murine tumor models. Effective imaging is achieved, and functional variations 
between mutants informs probe development. 
3.3. Materials and Methods 
3.3.1 Clone Production and Chelator Conjugation 
Affibody gene construction and ligand production were performed as described 
previously204. EA26S and EA62S genes were created through overlap extension PCR171, 
digested using BamHI-HF and NheI-HF restriction enzymes (New England Biolabs, 
Ipswich, MA), ligated into pET-22b vector containing a C-terminal hexa-histidine 
(Novagen, EMD Millipore, Billerica, MA) using T4 DNA ligase (New England Biolabs), 
and transformed into T7 express high efficiency Escherichia coli (New England Biolabs) 
via heat shock. EA68, EA35C, and EA35S plasmids, created previously204 and stored at -
20 °C, were also transformed into T7 express using the heat shock method. Proper 
transformants were selected on lysogeny broth (LB) based agar plates (15 g/L agar, 10 g/L 
tryptone, 10.0 g/L sodium chloride, 5.0 g/L yeast extract in H2O) containing kanamycin 
antibiotic (50 mg/L). After overnight growth at 37 °C, individual colonies were added to 5 
mL of liquid LB with kanamycin (50 mg/L) and shaken at 250 rpm, 37 °C until saturated 
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(8-12 h). Upon saturation, 1 mL of culture was added to 100 mL of sterile LB and shaken 
at 250 rpm, 37 °C until optical density values at 600 nm reached 0.5-1. Cells were induced 
with 100 μL of 0.5M isopropyl b-D-1-thiogalactopyranoside (IPTG) for 2 h at 25-28 °C. 
For instances where larger protein yields were required, production values were scaled to 
5 mL saturated culture, added to 1 L LB, and induced with 1 mL of IPTG; all other variables 
held constant. Production cultures were pelleted, supernatant discarded, and cells 
resuspended in lysis buffer (50mM sodium phosphate (pH 8.0), 0.5M sodium chloride, 5% 
glycerol, 5mM 3-[(3-cholamidopropyl)dimethylammonio]-1- propanesulfonate, and 
25mM imidazole). After four freeze-thaw cycles, cells were centrifuged at 12,000 g for 12 
min, and soluble fraction recovered. Hexa-histidine-tagged affibodies were isolated by 
immobilized metal affinity chromatography using 0.2 mL HisPur Ni-NTA resin (Thermo 
Fisher Scientific, Waltham, MA) spin columns (100 mL production culture) or 2 mL resin 
drip columns (1 L production culture). Protein concentration was determined using 
absorbance at 280 nm on a Synergy H1 microplate reader (BioTek, Winooski, VT). Large 
scale productions were further purified by reversed-phase high-pressure liquid 
chromatography (HPLC) with a C18 column and 15 min gradient of 25% to 80% elution 
buffer (90% acetonitrile, 9.9% H2O, 0.1% trifluoroacetic acid) with a running buffer of 
99.9% H2O, 0.1% trifluoroacetic acid. Clones were snap frozen in liquid nitrogen and 
lyophilized with a FreeZone Plus2.5 freeze-dry system (LabConco, Kansas City, MO). 
Affibodies used for PET/CT imaging were resuspended in dimethyl sulfoxide, 2-3% 
trimethylamine v/v, and either 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA)-ester (Macrocyclics Inc., Plano, TX) or 1,4,7-triazacyclononane,1-glutaric acid-
4,7-acetic acid (NODAGA)-ester (CheMatech, Dijon, France) at 3:1-10:1 molar ratios of 
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ester:protein. Upon conjugation, the reaction was quenched with excess 1 M Tris buffer, 
pH 8.0, isolated via HPLC, freeze-dried, and stored at 4 °C until used experimentally. 
3.3.2 Mammalian Cell Growth 
A431 epidermoid carcinoma (2.9 ± 1.4 x 106 EGFR/cell227), MDA-MB-435 
melanoma-type (1.5 ± 1.1 x 104 EGFR/cell227), and MCF7 (1.2 ± 1.5 x 102 EGFR/cell227) 
mammary carcinoma cell lines kindly provided by Dr. Daniel Vallera (University of 
Minnesota), Dr. Tim Starr (University of Minnesota), and Dr. Deepali Sachdev (University 
of Minnesota), respectively, were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37 °C, 5% 
CO2. 
3.3.3 Affinity Measurement, Target Specificity, and Circular Dichroism 
At 70-80% confluence, culture media was removed and 0.25% trypsin-EDTA in 
Hank’s Balanced Salt Solution (HBSS) (Corning, Tewksbury, MA) added for 6-10 min to 
detach cells. Cells were washed once with cold PBSA (phosphate buffered saline: 137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, and 1 g/L bovine serum albumin) 
to prevent EGFR internalization. Approximately 40,000 A431 or MCF7 cells were labeled 
with each affibody at varying concentrations (0-500 nM for affinity titrations and 500 nM 
for specificity tests) at 4 °C. Cells were again washed in cold PBSA and incubated with 
fluorescein-conjugated rabbit anti-His6 antibody (ab1206, Abcam, Cambridge, MA). 
Median fluorescence of each sample was determined with an Accuri C6 (BD Biosciences, 
San Jose, CA) and affinity values calculated by least squares regression assuming a 1:1 
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binding event between ligand and receptor. Equilibrium dissociation constants are 
presented as the average ± standard deviation of titrations.  
Lyophilized affibodies were resuspended to 0.5-1 g/L in 1xPBS. 300 μL of each 
suspension was added to a quartz cuvette with 1 mm path length and ellipticity measured 
from 200 to 260 nm at 20 °C on a Jasco J-815 spectrophotometer. Thermal denaturation 
curves were created by monitoring ellipticity at 220 nm as the sample was heated from 20 
to 98 °C at a rate of 2 °C/min. The midpoint of denaturation (Tm) was determined using a 
two-state protein unfolding model. After heating, suspensions were cooled to 20 °C and 
scanned from 200 to 260 nm to ascertain the degree to which each affibody refolds. 
3.3.4 Tumor Xenotransplantation 
Six-week-old female (Foxn1nu/Foxn1nu) mice (Jackson Labs, Bar Harbor, ME) 
were anesthetized with 2.0% isoflurane in 0.8-1 mL/min oxygen and subcutaneously 
injected in their right shoulder with approximately 10 million MDA-MB-435 cells in a 
50:50 v/v Matrigel Matrix/DMEM suspension. After 4.5 weeks, this method was repeated 
with approximately 4 million A431 cells injected subcutaneously into right shoulders. At 
six weeks after the MDA-MB-435 inoculation, xenografts from both tumor lines had grown 
to 4-11 mm in diameter. All animal studies were approved by the University of Minnesota 
Institutional Animal Care and Use Committee (Protocol 1411-32007A).  
3.3.5 64Cu Chelation of DOTA or NODAGA/Purification 
10-12 mCi of 64CuCl2 (University of Wisconsin) was suspended in 100 μL of 100 
mM NaAc, pH 5.0 for buffering and titrated to pH 6.0 using 0.1 M HCl and 0.1 M NaOH 
(final volume: 150-225 μL). 1-2 mCi of buffered 64CuCl2 was added to 500 μL of DOTA-
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affibody or 500 μL of NODAGA-affibody at 70-120 μM in PBS pH 7.4 or 10 mM sodium 
acetate pH 6.0 respectively and placed at 37 °C for 1 h to elicit complexation. 64Cu-DOTA-
affibody and 64Cu-NODAGA-affibody were separated from free copper using a PD-10 size 
exclusion column and PBS or 10 mM sodium acetate elution buffer. 
 
3.3.6 RadioTLC/Enzymatic Degradation 
64Cu-NODAGA-affibody purity levels and enzymatic degradation were ascertained 
with an AR-2000 radio-thin layer chromatography scanner (Eckert and Ziegler, Berlin, 
Germany). For determination of purity, 2 μL of PD-10 elution volume 3.5-4.0 mL was 
spotted on filter paper and a PBS mobile phase was used for migration. Area under the 
curve analysis was used to determine the fraction of unconjugated copper found in the 
solvent front peak compared to the relatively immobile 64Cu-NODAGA-affibodies. One 
μL from each 64Cu-NODAGA-affibody PD-10 elution volume 3.5-4.0 mL was added to 20 
μL of normal human serum (Jackson ImmunoResearch), normal mouse serum (Jackson 
ImmunoResearch), or 0.25% trypsin-EDTA in HBSS and incubated at 37 °C for 4 hours. 
Two μL samples were taken from each mixture at time points 1 and 4 h, spotted on filter 
paper (PBS mobile phase), and scanned to determine the relative percentage of affibody 
metabolites by means of area under the curve integration. 
3.3.7 PET Imaging/Quantification 
Mice were anesthetized under 2% isoflurane at 1 mL/min oxygen until no longer 
ambulant. Approximately 2.2 to 3.7 MBq of 64Cu-NODAGA- or 64Cu-DOTA-affibody, as 
determined by an Atomlab 100 dosimeter (Biodex, Shirley, NY) calibrated for 64Cu 
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measurements, was injected through lateral tail veins. Five-minute PET scans were 
performed at 1 and 4 h post-injection on an Inveon microPET/CT (Siemens, Malvern, PA) 
and reconstructed with 2D ordered-subset expectation maximization (OSEM2D). Four 
iterations of Fourier rebinning were performed. Photopeak energy cutoffs were set to 350-
650 keV with a time window of 3.438 ns. PET images were smoothed with a 1x1x1 voxel 
Gaussian filter. CT scans were executed using 340 projections of 80kV at 500 μA with 4x4 
binning and an effective pixel size of 85.6 μm. Scans ran for approximately 384 s and were 
reconstructed with the Feldkamp-David-Kress algorithm with slight noise reduction and 
Shepp-Logan filtering. 
PET image quantification was performed with Inveon Research Workplace 
software (Siemens). CT images were used as guides to determine 3D regional limits to 
tissues of interest including the liver, kidneys, thigh muscle, A431, and MDA-MB-435 
tumors. The maximum average PET signal in a 3x3x3 spherical voxel (9.1 mm3) was 
determined for each tissue type. 
3.3.8 Tissue Quantification 
After imaging, mice were euthanized by cervical dislocation while still under 
isoflurane anesthesia. After verifying death via toe pinch, mice were dissected and blood, 
heart, lung, liver, pancreas, spleen, stomach, intestine, skin, A431 tumor, MDA-MB-435 
tumor, brain, bone, muscle, and kidneys were collected and weighed. Sample radioactivity 
was measured by either a CRC 25W (Capintec, Florham Park, NJ) gamma counter over all 
energy ranges or an Automatic Gamma Counter (Hidex, Turku, Finland) between 400 and 
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600 keV with all reads averaged over 60 s. Counts from both instruments were calibrated 
using serial dilutions based on the dose reported by the Atom Lab 100 dosimeter. 
3.3.9 Statistics 
Comparisons for statistical significance were performed using two-tailed student’s 
t-tests assuming unequal variance. Values are reported as mean ± standard error unless 
otherwise stated. 
3.4. Results and Discussion  
3.4.1 Further charge modulation of EA35S -- guided by sequence tolerance data from 
high throughput selections -- is well tolerated with regards to secondary structure, 
stability, affinity, and recombinant yield. 
In a previous study204, 3 basic and 3 acidic residues from the EGFR-targeted 
affibody EA68 were neutralized via mutation yielding 19 mutants of which clones ‘EA35S’ 
and ‘EA35C’ retained the greatest combination of target affinity, thermal stability, and 
recombinant yield. While these clones enable the evaluation of charge density reduction 
on physiological distribution, additional variations of net charge were desired. Based on 
the success of the ‘synthetic consensus’ strategy for identifying mutants with three basic 
and five acidic residues (+3/-5)204 the approach was used to identify alternative mutations. 
The most frequently observed neutralizing mutations – within the previously enriched 
affibody mutants – were chosen to mutate EA35S to create clones with +2/-6 (EA26S) and 
+6/-2 (EA62S) charge (Figure 3-1) with the exception of position 47 in EA62S. Although 
not tested in the synthetic approach, site 47 was mutated to glutamine as necessary based 
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on the prevalence of accepted glutamic acid to glutamate replacements at other sites, E14 
residing in the paratope, and residue 36 remaining negatively charged (glutamic of aspartic 
acid) in 98% of natural homologs.  
 
Figure 3-1. Affibody mutants. (A) Structural schematics of affibody clones EA68, 
EA35C, EA35S, EA26S, and EA62S. Acidic, basic, and charged-to-neutral mutated 
residues are designated as red, blue, and green, respectively. Structures are based on 
PDB 1H0T133. (B) Sequences of the affibody mutants with the same color scheme as 
in (A). The traditional paratope regions are shown in bold. 
EA26S and EA62S were readily produced and purified from the soluble fraction of 
E. coli culture (0.62 ± 0.02 mg/L and 1.9 ± 0.3 mg/L, respectively). The purified proteins 
were titrated for binding to EGFR-overexpressing A431 cells and evaluated by flow 
cytometry. EA26S and EA62S bind with high affinity (1.6 ± 1.2 nM and 2.5 ± 0.7 nM, 
respectively; Figure 3-2A) comparable to EA35S (1.7 ± 0.5 nM) and exceeding the EGFR 
affinities of both EA68 (5.3 ± 1.7 nM) and EA35C (6.9 ± 1.4 nM). Binding is molecularly 





Figure 3-2. Binding characterization. (A) EGFRhigh A431 cells were mixed with the 
indicated concentration of affibody (EA26S (blue circles) or EA62S (green squares)). 
Binding was detected with fluorophore-conjugated anti-His6 antibody via flow 
cytometry. Equilibrium dissociation constants were calculated assuming a 1:1 
binding model. n = 3 measurements per variant. (B) EGFRhigh A431 cells (white) or 
EGFRlow MCR7 cells (black) were incubated with 500 nM affibody. Binding was 
detected as in (A). n = 3 measurements per variant. 
Like EA35S and EA35C, the new variants exhibit comparable secondary structure 
and ability to refold after thermal denaturation to the parental EA68 (Figure 3-3A,B). 
EA26S exhibits thermal stability (Tm = 68 ºC) comparable to EA68, EA35C, and EA35S 
(71, 71, and 68 ºC, respectively) whereas EA62S is less stable (Tm = 59 ºC) (Figure 3-3C). 
 
Figure 3-3. Structural characterization. Purified EA26S and EA62S were evaluated by 
circular dichroism. (A,B) Wavelength scans from 200 nm to 260 nm before (solid line) 
or after (dotted line) heating to 98 ºC and cooling to 20 ºC. (C) Thermal scan from 20 
ºC to 98 ºC at a wavelength of 220 nm. 
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 Thus, the collection of EGFR-binding affibodies exhibits similar biophysical 
properties but varied charge distribution (Table 3-1). 
Table 3-1. Biophysical properties of affibody clones used for PET/CT imaging.  
 
The efficacy of consensus design based on synthetic combinatorial library 
selections is consistent with previous efforts.168,204 This efficacy may also be supported by 
the robustness of the previously improved affibody framework.144 The resultant ability to 
modulate charge yielded a set of affibody variants that enable evaluation of the 
physiological effects of these mutations, which include changes in net charge and charge 
density. 
3.4.2 Affibody variants are functional EGFR imaging probes 
The parental EA68 and the four neutralized charge variants with a range of net 
charge were conjugated with 2,2′-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-
oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid, the N-hydroxysuccinimidyl ester of 
NODAGA. Conjugation was verified by matrix-assisted laser desorption ionization 
(MALDI) mass spectrometry (Figure 3-4) and showed an average labeling of 1.7, 1.7, 1.5, 






Figure 3-4. Conjugation of NODAGA to affibody charge variants. Matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS) of NODAGA-affibody charge 
variants with 0, 1, 2, or 3 degrees of conjugation 
While more site-selective conjugation could have been achieved with unique 
cysteine incorporation or alternative approaches, the amine-conjugated affibodies 
exhibited similar target affinities to their unconjugated forms (Figure 3-5).  
 
Figure 3-5. NODAGA-affibody target-affinity characterization. EGFR-overexpressing 
A431 cells were mixed with the indicated concentration of NODAGA-conjugated 
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affibody. Binding was detected with fluorophore-conjugated anti-His6 antibody via 
flow cytometry. Equilibrium dissociation constants were calculated assuming a 1:1 
binding model. n = 3 measurements per variant. NODAGA-conjugated versions of 
EA35S and EA26 were nominally weaker binders to EGFR than their unconjugated 
counterparts (Kd = 3.9 ± 0.4 nM vs. 1.7 ± 0.5 nM and 4.6 ± 0.3 vs. 1.6 ± 1.2 nM 
respectively). However, these variances are slight and should not meaningfully impact 
in vivo biomarker localization. EA68 and EA62 showed no difference in binding 
affinity upon NODAGA conjugation and EA35C presented a slight improvement (4.3 
± 0.3 nM vs. 6.9 ± 1.4 nM). 
Each NODAGA-conjugated affibody was mixed with 1 - 1.5 mCi of 64Cu in 100 
mM sodium acetate buffer at pH 6.0 to undergo complexation at 37 °C for 1 h. 
Radiolabeled proteins were separated from free 64Cu through size exclusion 
chromatography, yielding high radiochemical purity (96 - 99%) and labeling efficiency (65 
± 6%) for subsequent murine injections. By applying knowledge of previous purifications 
of their non-radiolabeled forms, approximate specific activities were calculated between 
0.4 - 1.1 MBq/nmol.  
Imaging performance and physiological distribution were evaluated in mice 
harboring dual xenografted tumors: EGFRhigh A431 and EGFRlow MDA-MB-435. 64Cu-
complexed affibodies were injected via tail vein, and PET/computed tomography (CT) 
images were collected at 1 and 4 h post-injection. CT scans were used as locational guides 
to determine regions of interest including the liver, kidneys, muscle (anterior/posterior 
thigh), A431, and MDA-MB-435 tumors. All affibody variants exhibited strong EGFR 




Figure 3-6. PET/CT imaging. Mice with xenografted A431 (EGFRhigh) and MDA-MB-
435 (EGFRlow) tumors in either shoulder were injected intravenously with 64Cu-
NODAGA-affibody (five different variants) and imaged via PET/CT at 1 h and 4 h 
post-injection. Coronal and axial slices through the tumor are shown for 
representative mice (n = 3 - 7). 
 
 
Figure 3-7. PET imaging quantification. Mice (n = 3 - 7) with xenografted A431 
(EGFRhigh) and MDA-MB-435 (EGFRlow) tumors in either shoulder were injected 
intravenously with 64Cu-NODAGA-affibody (five different variants) and imaged via 
PET/CT at 1 h (solid) and 4 h (checkered) post-injection. Signal in the liver, tumors, 
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muscle, and kidney were quantified using Siemens Inveon Research Workplace 
software. * designates p < 0.01. 
At 1 h, the five affibodies had localized to EGFR-overexpressing A431 tumors with 
molecular specificity (5.2 ± 0.5 %ID/g) and cleared from EGFRlow MDA-MB-435 tumors 
(1.6 ± 0.1 %ID/g). By 4 h, A431 signal had increased further (6.7 ± 0.5 %ID/g) while 
MDA-MB-435 remained low and decreased slightly (1.2 ± 0.1 %ID/g). Among clones, 
EA35S displayed the nominally highest EGFR-binding at both 1 h (6.7 ± 1.6 %ID/g) and 
4 h (7.7 ± 1.4 %ID/g). As is common with renal clearance of small proteins, high levels of 
kidney signal were prevalent, and average concentration exceeded 50 %ID/g for all clones. 
Note that due to the large number of photons emanating from the kidneys, multiple 
coincident events may be detected within the allotted time window forcing some events to 
be discarded to avoid locational ambiguity. This can result in kidney activity measurements 
being artificially lower than their true values and cross-comparison among clones may not 
be valid228. Background clearance was rapid with an average muscle signal of 0.8 ± 0.1 
%ID/g at 1 h which decreased to 0.6 ± 0.1 %ID/g by 4 h. Excluding EA62S, clones 
exhibited moderate levels of liver signal due to hepatic processing at both 1 h (4.8 ± 0.3 
%ID/g) and 4 h (4.6 ± 0.3 %ID/g). Conversely, EA62S had significantly greater hepatic 
retention than all other clones at both 1 h (13.5 ± 0.7 %ID/g, p < 0.01) and 4 h (13.6 ± 0.9 
%ID/g, p < 0.01). 
Imaging results were corroborated by analysis of excised tissues at 4 h post-
injection (Figure 3-8). The parental protein, EA68, exhibited strong EGFR-specific tumor 
uptake (7.2 ± 1.5 %ID/g in EGFRhigh versus 0.9 ± 0.2 %ID/g in EGFRlow; p = 0.002; Figure 
3-8A). Specificity was further supported by 11 ± 4 tumor:blood and 126 ± 56 tumor:muscle 
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ratios (Figure 3-8B). Retention is substantial in kidneys (169 ± 12 %ID/g) and modest in 
liver (4.5 ± 0.6 %ID/g). Similarly, EA35C displayed elevated EGFRhigh (7.0 ± 0.9 %ID/g) 
and low EGFRlow tumor (1.5 ± 0.4 %ID/g) signal with substantial tumor:blood (11 ± 4 
%ID/g) and tumor:muscle (151 ± 70 %ID/g) ratios. EA35S showed the highest level of 
A431 retention (12 ± 2 %ID/g) but a nominally elevated hepatic signal (7 ± 1 %ID/g) 
versus clones EA35C, EA26S, and EA68 which averaged 4.4 ± 0.3 %ID/g in the liver. 
Compared to all other variants, which are negatively charged, positively charged EA62S 
has significantly higher liver and spleen retentions of 14 ± 1 %ID/g (p ≤ 0.01) and 3.2 ± 
0.3 %ID/g (p ≤ 0.01) respectively.  
 
Figure 3-8. Excised tissue analysis. Mice with xenografted A431 (EGFRhigh) and 
MDA-MB-435 (EGFRlow) tumors in either shoulder were injected intravenously with 
64Cu-NODAGA-affibody (five different variants) and euthanized at 4 h post-injection. 
Tissues or fluid was excised and weighed; radioactivity was measured (n = 3-7). **: p 
< 0.01, *: p < 0.05. 
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The rapid distribution of the affibody probes, as well as clearance of unbound 
probe, enables effective imaging at early time points. While not requisite for diagnostic 
imaging, additional studies could be used to evaluate probe localization at later times. 
3.4.3 Chelator Comparison 
To determine the effect that chelator may have on biodistribution, EA68 and EA35S 
were conjugated with the DOTA by reaction of N-hydroxysuccinimidyl-DOTA ester 
with primary amines on the N-terminus or lysine residues of each protein. MALDI-
MS was used to verify an average labeling of 1.1 DOTA per EA68 and 2.0 DOTA 
per EA35S affibody (Figure 3-9).  
 
Figure 3-9. Conjugation of DOTA to EA68 and EA35S. Matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS) of DOTA-EA68 and DOTA-
EA35S with 0, 1, 2, or 3 degrees of conjugation 
DOTA labeled EA68 and EA35S were mixed with 1.9 - 2.0 mCi of 64Cu in 
PBS at pH 7.4 to undergo complexation at 37 °C for 1 h. Size exclusion chromatography 
was used to separate complexed affibodies from free 64Cu providing a labeling efficiency 
of 43% and 60% for 64Cu-NODAGA-EA35S and 64Cu-NODAGA-EA68. The approximate 
specific activities of EA35S and EA68 were 0.25 and 0.33 MBq/nmol. 
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Chelator performance was evaluated in six nude mice with human EGFRhigh A431 
and EGFRlow MDA-MB-435 tumors xenografts. A431 xenotransplantation and subsequent 
growth was successful in all murine models. However, four of six mice showed no 
measurable MDA-MB-435 tumor progression. The remaining two mice displaying both 
cancer lines were split to provide one negative control tumor for each DOTA-conjugated 
affibody. Mice were injected intravenously through lateral tail veins with 2.3 - 3.7 MBq of 
64Cu-NODAGA-EA35S and 64Cu-NODAGA-EA68. At 4 h post-injection mice were 
euthanized, tissues excised, and blood collected. 
The use of a NODAGA chelator yields lower signal in all background (i.e. non-
A431 tumor) tissues in comparison to DOTA (Figure 3-10). 64Cu-NODAGA-EA35S 
maintained significantly lower blood, heart, liver, and stomach uptake than 64Cu-DOTA-
EA35S. Similarly, 64Cu-NODAGA-EA68 had substantially lower signal in the lungs and 
intestine than 64Cu-DOTA-EA68. EGFRhigh A431 tumor localization was comparable (and 
nominally greater) for both NODAGA-labeled EA35S and EA68 than their DOTA-
conjugated counterparts. These results are consistent with previous data indicating 
imperfect stability of the 64Cu-DOTA complex in vivo.229 
As numerous EGFR PET probes are in preclinical development, performance 
comparison is desirable. Strict quantitative comparisons have moderate utility because of 
differences in tumor models and experimental procedures but can provide guidance when 
such differences are limited and acknowledged. The current 64Cu-NODAGA-EA35S 
exhibits comparable tumor uptake and tumor:muscle specificity but superior tumor:blood 
(12 ± 3 vs. 1.0 ± 0.1 without blocking) and liver specificity (5.2 ± 0.8 %ID/g vs. 19 ± 3 
%ID/g) relative to a Miao et al. study230 with 64Cu-DOTA-affibody1907. The chelator 
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comparison experiments (Figure 3-10) reveal that this benefit derives predominantly from 
the use of NODAGA as the 64Cu-DOTA-affibody results are comparable between the 
current study and Miao et al. and similarly matched by an additional study with a Hep3B 
xenograft.231 Other alternative radiochemistries, with 89Zr-DFORef. 212 or 18F-CBTRef. 213, 
also reduce hepatic signal albeit without benefit to tumor:blood specificity. Strong 
tumor:blood specificity was achieved with the 64Cu-DOTA-affibody via a small dose of 
unlabeled affibody.230 The previous 64Cu-DOTA-affibody1907 and the current 
64Cu-DOTA-
EA68 only differ in the current use of the engineered protein framework, optimized by 
Feldwisch et al.144 for enhanced stability and reduced immunoglobulin binding. Thus, by 
historical comparison, these mutations enable these benefits without substantially altering 
physiological delivery; yet direct comparison in the same experimental system would be 
needed to discern potential differences more precisely. The current 64Cu-NODAGA-
affibodies yield comparable PET imaging and physiological delivery performance to a 
64Cu-DOTA-Gp2 probe214 and higher tumor sensitivity and tumor:muscle specificity 





Figure 3-10. Chelator comparison. Mice with xenografted A431 (EGFRhigh) and 
MDA-MB-435 (EGFRlow) tumors in either shoulder were injected intravenously with 
64Cu-NODAGA-affibody or 64Cu-DOTA-affibody and euthanized at 4 h post-
injection. Tissues or fluid was excised and weighed; radioactivity was measured (n = 
3 - 7). * designates p < 0.05. 
3.4.4 Labeling and Serum Stability 
In vitro enzymatic stability was assessed through radio-thin-layer chromatography. 
Radiolabeled charge variants were added to murine serum, human serum, or trypsin-EDTA 
(0.25%) in HBSS at a 1:20 volumetric ratio and incubated for 4 hours at 37 °C. Area under 
the curve analysis shows that parental EA68 was most resistant to degradation in both 
human and murine serum to similar degrees. Approximately 2% and 4% of sample signal 
contained 64Cu-labeled metabolites at both 1 and 4 h in human and murine serum, 
respectively (Figure 3-11). Similarly, EA35C and EA26S were stable in human serum with 
6% and 4% of total signal area due to proteolysis after 4 hours. EA35S and EA62S 
degraded more rapidly, with 10% and 11% of cleaved 64Cu-peptide in human serum at 4 
h. Excluding EA68, clones were more susceptible to enzymatic cleavage in murine serum 
than human serum. This difference was most pronounced in clones EA26S and EA62S, 
where 16% and 44% of radioactivity was attributed to metabolic product in mouse serum 
versus 4% and 11% for human serum. In all cases, trypsin digestion resulted in hydrolysis 




Figure 3-11. Proteolytic stability. Radio chromatography of affibody clones left 
untreated, in serum, or in trypsin. 
3.5. Conclusions  
Molecular imaging of EGFR is poised to address an important clinical need: to 
stratify a subset of cancer patients as responders vs. nonresponders to several molecularly 
targeted therapies to enable effective treatment planning. While numerous probes have 
undergone preclinical development, further molecular advances are needed as no clinical 
imaging probe is yet available for EGFR. Charge has been shown to play an important role 
in physiological distribution of proteins, but system complexity precludes a priori design 
and necessitates experimental evaluation. We have further demonstrated the efficacy of 
‘synthetic consensus design’ in identifying functional neutralizing mutations to yield a set 
of small affibody scaffolds varied in net charge and charge density. Evaluation of this set 
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of probes, radiolabeled with 64Cu, for PET imaging of EGFR in mouse tumor models 
reveals sensitive, specific molecular imaging for multiple variants with notable differences 
in liver retention, specificity, and probe stability for different charge and chelator designs. 
Elucidation of these differential efficacies aids engineering of an ideal probe for 
translational studies. 
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Chapter 4 - Engineered charge redistribution of Gp2 proteins 
through guided diversity for improved PET imaging of 
epidermal growth factor receptor 
4.1. Outline 
The Gp2 domain is a protein scaffold for synthetic ligand engineering. However, 
the native protein function results in a heterogeneous distribution of charge on the 
conserved surface, which may hinder further development and utility. We aim to modulate 
charge, without diminishing function, which is challenging in small proteins where each 
mutation is a significant fraction of protein structure. We constructed rationally guided 
combinatorial libraries with charge-neutralizing or charge-flipping mutations and sorted 
them, via yeast display and flow cytometry, for stability and target binding. Deep 
sequencing of functional variants revealed effective mutations both in clone-dependent 
contexts and broadly across binders to epidermal growth factor receptor (EGFR), insulin 
receptor, and immunoglobulin G. Functional mutants averaged 4.3 charge neutralizing 
mutations per domain while maintaining net negative charge. We evolved an EGFR-
targeted Gp2 mutant that reduced charge density by 33%, maintained net charge, and 
improved charge distribution homogeneity while elevating thermal stability (Tm = 87 ± 1 
ºC), improving binding specificity, and maintaining affinity (Kd = 8.8 ± 0.6 nM). This 
molecule was conjugated with 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid for 
64Cu chelation and evaluated for physiological distribution in mice with xenografted A431 
(EGFRhigh) and MDA-MB-435 (EGFRlow) tumors. Excised tissue gamma counting and 
positron emission tomography / computed tomography imaging revealed good EGFRhigh 
tumor signal (4.7 ± 0.5 %ID/g) at 2 h post-injection and molecular specificity evidenced 
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by low uptake in EGFRlow tumors (0.6 ± 0.1 %ID/g, significantly lower than for non-
charge-modified Gp2, p = 0.01). These results provide charge mutations for an improved 
Gp2 framework, validate an effective approach to charge engineering, and advance 
performance of physiological EGFR targeting for molecular imaging. 
4.2. Introduction 
Small protein ligands that bind targets with high affinity and specificity are valuable 
resources for imaging131,198, therapeutic232–234, and diagnostic purposes182,183. Small 
scaffolds benefit from increased tumor extravasation36,235,236, tissue penetration192,237 and 
plasma clearance36,238 resulting in improved target-to-background contrast at early time 
points128–130. Protein ligands must be engineered for not only binding function but also 
physicochemical robustness and physiological performance. To optimize performance, 
several influencing factors have been studied including scaffold structure185, 
hydrophilicity38,186, stability187,239, and charge38,80,189. Protein charge is of considerable 
interest as clusters of positively charged residues can reduce solubility67 and drive 
nonspecific binding to native negatively charged cell membranes68–70. An increase in the 
fraction of charged residues on nonparatope regions can correspond to decreased target 
affinity74. Ligand charge can also affect transvascular flux75,78, tumor uptake77, plasma 
clearance71,158, and renal retention38,79. It is therefore important to be able to modulate 
charge without diminishing desirable ligand characteristics including high production yield 
and soluble recovery, strong affinity, and stability. However, these charge modifications 
can be particularly difficult in the context of a small ligand38,193 where such mutations 
would encompass a greater portion of the protein’s structure98. 
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A scaffold that may benefit from redistributed and reduced charge is the Gp2 
domain149. Gp2 is a small, stable 45-residue scaffold with -helical and -strand structure 
whose solvent-exposed loop regions have been diversified to discover and evolve binders 
to numerous targets.149 Engineered Gp2 domains have been validated for molecular 
positron emission tomography (PET) imaging of epidermal growth factor receptor 
(EGFR)214 and antagonism of insulin receptor (InsR) in tamoxifen-resistant, triple-negative 
breast cancer cell culture240. The native Gp2 framework contains three positive and six 
negative residues, with each charge set regionally clustered. It is hypothesized that this 
charge distribution evolved in wild-type Gp2 because of its native function. In a Gp2-RNA 
polymerase model structure, the string of acidic residues projects into the DNA-binding 
channel thereby aiding inhibitory function.134 Also, the basic residues R42 and R44 were 
experimentally shown as necessary for Gp2 function as they aid binding to RNA 
polymerase.134 Yet maintenance of these charges is not necessary – and we hypothesize 
not optimal – for its newfound role as a scaffold for synthetic ligand engineering. These 
highly charged regions may drive nonspecific binding73, off-target retention38,79,80,82, and 
decrease protein yield during ligand production due to reduced solubility151–153. Therefore, 
the ability to mutate such clusters without reducing Gp2 affinity or stability has 
considerable value. 
Numerous strategies exist for charge engineering including computational 
design151,241,242, homology-guided consensus design162, and combinatorial library 
selection204. We merged versions of each of these techniques to identify charge-modifying 
mutations that are well tolerated in multiple Gp2 domains and applied effective mutations 
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to an EGFR-binding Gp2 domain for PET imaging. EGFR overexpression is present in 
numerous cancers161, is correlated with differentiation, and is an independent prognostic 
indicator of poor disease-free and overall survival in colorectal cancer patients243,244. 
Molecular imaging of EGFR could empower patient stratification of responders versus 
nonresponders to molecularly targeted therapy.110,115 
Combinatorial libraries of Gp2 mutants targeting EGFR, InsR, and rabbit 
immunoglobulin G (rIgG), guided by computational stability245 as well as natural163,164 and 
chemical homologs246, were sorted via yeast display and flow cytometry for mutants that 
retained thermal stability and target affinity. Functional mutants elucidated preferred net 
and total charge states, determined favored amino acids at charged positions, and identified 
several promising charge-modified anti-EGFR Gp2 ligands. A charge-reduced clone, 
GαE35, exhibited reduced nonspecific binding and highly functional performance in 
PET/CT imaging of EGFR+ tumors in murine models. The results advance Gp2 scaffold 
engineering, as well as charge engineering more broadly, and improve preclinical 
performance of an EGFR PET agent. 
4.3. Materials and Methods 
4.3.1 FoldX and Homolog Consensus 
FoldX245 was used to predict destabilizing effects of residue mutations at charged 
positions by estimating the change in free energy of folding for these mutations on the Gp2 
scaffold. Calculations were performed at each position using 40 randomized paratopes, or 
until < 0.1 kcal mol-1 absolute or < 1% relative deviation in mean was achieved with each 
additional variant for four solved crystal structures of T7 phage Gp2 (2LMC247, 2WNM134, 
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4LLG248, 4LK0248) and averaged to determine the final ΔΔGfolding,mutation of each canonical 
amino acid at all positions. 
We searched for homologs of the wild-type Gp2 protein via NCBI BLAST249 (in 
2016) resulting in 32 sequences, which were aligned in ClustalW2250. Sitewise amino acid 
frequencies were calculated.  
4.3.2 Library Construction 
Degenerate oligonucleotides containing the mixed bases necessary for desired 
residue mutations at charged positions and encoding for GαE2.2.3, GαI2.2.5, or GαR3.2.3 
paratope regions were purchased (IDT DNA, Coralville, IA) and assembled via PCR 
overlap extension. Each of the three libraries was transformed into the yeast surface display 
strain EBY100167 using homologous recombination with a linearized pCT vector as 
described172. Transformation efficiency was determined by serial dilution on SD-
CAA/agar plates (0.07 M sodium citrate (pH 5.3), 6.7 g/L yeast nitrogen base, 5 g/L 
casamino acids, 20 g/L glucose, and 15-18 g/L bacto agar in water). Sanger and Illumina 
sequencing of each library was performed to verify proper transformation. 
4.3.3 Binder Selection and Illumina Sequencing 
Yeast were grown in SD-CAA (0.07 M sodium citrate (pH 5.3), 6.7 g/L yeast 
nitrogen base, 5 g/L casamino acids, and 20 g/L glucose in water) and induced in SG-CAA 
(0.1M sodium phosphate (pH 6.0), 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 19 
g/L galactose, and 1 g/L glucose in water) at 30 ºC, 250 rpm as described.172 Populations 
with sample sizes between 10x and 20x of theoretical diversity were taken from naïve 
libraries and sorted using flow cytometry. Yeast were washed in phosphate-buffered saline 
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with 1 g/L bovine serum albumin (PBSA) heated to 50-80 °C for 30 min, cooled on ice to 
4 °C, incubated with 2 – 20 nM recombinant, biotinylated target protein and anti-c-Myc 
antibody (Cat# 626802, BioLegend, San Diego, CA) to isolate full-length Gp2 mutants and 
account for differences in surface expression, labeled with streptavidin-Alexa Fluor 647 
(Life Technologies, Waltham, MA) and goat anti-mouse-FITC antibody (Cat# F0257, 
Sigma–Aldrich, St. Louis, MO), then sorted.  
Because yeast cell viability diminishes significantly above 42 °C251, the recovered 
populations in heat-treated sorts always exceeded 105 yeast cells. This number of cells 
provided sufficient plasmid reclamation for the resulting downstream plasmid recovery via 
Zymoprep protocol (Zymo Research, Irvine, CA), PCR amplification of Gp2 genes, and 
retransformation through electroporation into yeast to rebuild display libraries for 
continued sorting. After their final recombinant target sorts, Gp2 libraries were exposed to 
avidin-coated magnetic beads (Invitrogen, Waltham, MA), followed by beads with 
immobilized nontarget mouse IgG; nonbinding yeast were collected and sequenced. 
The EGFR-binding population underwent two additional rounds of sorting without 
heating against 0.2 and 2 nM solubilized EGFR from A431 cell lysate as described 
previously.252 Briefly, after reaching 70-80% confluency, A431 cells were detached, 
washed in ice-cold PBS, incubated with NHS-PEG4-Biotin, lysed and centrifuged, and the 
resulting supernatant mixed with Gp2 expressing yeast recovered from bead depletion. 
Binding was detected via flow cytometry as for recombinant target selections. 
Illumina MiSeq paired-end sequencing was used to obtain 4.7 x 105, 1.6 x 104, 5.9 
x 104, and 8.9 x 105, 4.9 x 104, 5.9 x 104 reads from the naïve and sorted binding populations 
of EGFR, InsR, and rIgG Gp2 libraries. Forward and reverse reads were aligned using 
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PANDAseq253 with a 90% quality cutoff resulting in 2704, 2840, 595, and 3202, 797, 171 
unique sequences from naïve and enriched populations in EGFR, InsR, and rIgG libraries. 
Sequences were sorted, aligned, and sitewise frequencies calculated. Clones appearing 
more than once had frequencies dampened by √𝑛 where n represents the number of clonal 
occurrences found in the Illumina sequences. 
4.3.4 Mammalian Cell Growth 
MDA-MB-435 melanocyte ((1.5 ± 1.1) x 104 EGFR per cell227) and A431 
epidermoid carcinoma ((2.9 ± 1.4) x 106 EGFR per cell227) cell lines were kindly provided 
by Dr. Tim Starr (University of Minnesota) and Dr. Daniel Vallera (University of 
Minnesota). Both cell lines were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 1% penicillin streptomycin and 10% fetal bovine serum at 37 °C in 
humidified air with 5% CO2. When needed experimentally, cultures were incubated with 
1-2 mL of 0.25% Trypsin-EDTA for 6-10 min to detach cells. 
4.3.5 GαE Clonal Production and Characterization 
Gp2-encoding regions in DNA recovered from the final lysate-extracted EGFR 
flow cytometry sort were amplified by polymerase chain reaction, digested with NheI-HF 
and BamHI-HF restriction enzymes (New England Biolabs, Ipswich, MA), and ligated into 
a pET-22b vector containing a C-terminal hexa-histidine (Novagen, EMD Millipore, 
Billerica, MA) with T4 DNA ligase (New England Biolabs). Plasmids were transformed 
via heat-shock into T7 Express Competent E. coli (New England Biolabs) and proper 
transformants selected on lysogeny broth (LB) plates containing 50 mg/L kanamycin. 
Surviving colonies were added to 4 mL liquid LB/kanamycin (50 mg/L) and incubated in 
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shake flasks at 37 °C, 250 rpm for 10-16 h. Saturated cultures were added to 100 mL of 
LB, incubated 37 °C, 250 rpm until reaching an optical density between 0.5 and 1.0 upon 
which 0.1 mL 0.5 mM isopropyl β-D-1-thiogalactopyranoside was added to induce protein 
expression. Induced cultures were incubated 4-24 h at 30 °C, 250 rpm, cells were pelleted 
and resuspended in lysis buffer (50mM sodium phosphate (pH 8.0), 0.5M sodium chloride, 
5% glycerol, 5mM 3-[(3-cholamidopropyl)dimethylammonio]-1- propanesulfonate, and 
25mM imidazole), frozen and thawed 4 times, centrifuged for 10 min at 10 °C, and the 
resulting cell lysate run through 0.2 mL Cobalt HisPur resin volume spin columns (Thermo 
Fisher Scientific, Waltham, MA) to recover Gp2 proteins. When greater levels of Gp2 
production were required, as in the case of murine PET/CT imaging studies, saturated 
cultures were added to 1 L LB and clones were recovered using 2 mL Cobalt HisPur resin 
volume gravity columns. Recovered yields were assessed using absorbance at 280 nm on 
a Synergy H1 microplate reader (BioTek, Winooski, VT). 
In some cases, clones were additionally purified by reversed-phase high-
performance liquid chromatography with a C18 column using a 15 min gradient of 10% to 
90% elution buffer (90% acetonitrile, 9.9% water, 0.1% trifluoroacetic acid) and the 
remaining solution composed of running buffer (99.9% water, 0.1% trifluoroacetic acid). 
Recovered Gp2 was lyophilized. 
Secondary structure, midpoint of thermal denaturation (Tm), and protein refolding 
after heating was determined using circular dichroism performed on a Jasco J-815 
spectrophotometer with samples placed in a 1 mm path length quartz cuvette. Purified and 
lyophilized Gp2 ligands were resuspended in PBS to 0.2-1 mg/mL. Ellipticity was 
measured between 205 and 260 nm wavelengths at 20 °C before and after heating to 98 °C. 
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Thermal denaturation was evaluated at 220 nm during sample heating at 2 °C/min from 20 
°C to 98 °C. 
At 70-80% confluence, A431 were detached as described previously, pelleted, and 
resuspended in 4 °C PBSA. Each Gp2 ligand was added at varying concentrations (0, 2, 
20, 50, and 500 nM) to 50,000 resuspended A431 cells and incubated at 4 °C to allow for 
EGFR binding. Cells were again pelleted and washed with cold PBSA, then incubated with 
fluorescein-conjugated anti-His6 antibody (Abcam, Cambridge, MA). Cells were washed 
a final time and analyzed for fluorescence using flow cytometry on an Accuri C6 (BD 
Biosciences, Franklin Lakes, NJ). Using median fluorescence at each ligand concentration, 
the equilibrium dissociation constant, Kd, was determined by minimizing the sum squared 
errors assuming a 1:1 binding interaction. Affinity titrations were performed thrice. To 
elucidate EGFR specificity, an analogous procedure was performed with A431 and MDA-
MB-435 cell lines at 500 nM target (n = 3). 
Gp2 ligands used for PET/CT imaging were resuspended in dimethyl sulfoxide, 2-
3% trimethylamine v/v, and 1,4,7-triazacyclononane,1- glutaric acid-4,7-acetic acid 
(NODAGA)-ester (CheMatech, Dijon, France) at 5:1-10:1 molar ratios of ester:protein. 
Upon conjugation as verified by matrix-assisted laser desorption ionization mass 
spectrometry, the reaction was quenched with excess 1 M Tris buffer, pH 8.0, isolated via 
HPLC, freeze-dried, and stored at 4 °C until use. 
4.3.6 Tumor Xenotransplantation 
Six-week-old female (Foxn1nu/Foxn1nu) mice (Charles River Laboratories, 
Wilmington, MA) were anesthetized via inhalation of 2% isoflurane in 1-1.2 mL min-1 O2. 
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Ten million MDA-MB-435 cells, suspended in a 50:50 v/v DMEM/Matrigel Matrix 
solution, were subcutaneously injected in their right shoulder. After 4.5-5 weeks, this 
process was repeated with 7 million A431 cells subcutaneously injected into the opposing 
shoulder. Xenograft tumors were grown to 5-12 mm in diameter (approximately 6 weeks 
after MDA-MB-435 inoculation). In preblocking experiments, this procedure was repeated 
with 7 million A431 cells subcutaneously injected into both shoulders followed by 1.5 
weeks of tumor growth until tumor diameters reached 7-10 mm.  
4.3.7 Chelation and Purification 
5-12 mCi 64CuCl2 (University of Wisconsin-Madison) was diluted in 100 µL 100 
mM sodium acetate pH 6.0 to provide buffering, then titrated with 1 M sodium hydroxide 
and 1 M hydrochloric acid to a final pH of 6.0 as confirmed by narrow band pH paper (final 
volume: 200-250 µL). 1-2 mCi buffered 64CuCl2 was added to 50-120 µM NODAGA-Gp2 
in 10 mM sodium acetate pH 6.0 and incubated at 42 °C for 1 h to enact complexation. 
64Cu-NODAGA-Gp2 ligands were separated from free 64Cu through size exclusion 
chromatography with PD-10 columns pre-equilibrated with 10 mM sodium acetate pH 6.0. 
4.3.8 RadioTLC/Enzymatic Degradation 
64Cu-NODAGA-Gp2 purity and enzymatic stability were determined with an AR-
2000 radio-thin-layer chromatography scanner (Eckert and Ziegler, Berlin, Germany) as 
described previously254. Briefly, 1-2 μL PD-10 elution volume 3.5-4.0 mL was spotted on 
chromatography paper with PBS used as the mobile phase to separate any uncomplexed 
copper from 64Cu-NODAGA-Gp2. Through integration analysis of the resulting position 
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vs. scintillation count data, relative fractions of free 64Cu and 64Cu-NODAGA-Gp2 were 
determined. 
To ascertain enzymatic stability, 1 μL from 64Cu-NODAGA-Gp2 PD-10 elution 
volume 3.5 – 4.0 mL was added to 20 μL normal human serum (Jackson 
ImmunoResearch), normal mouse serum (Jackson ImmunoResearch), or 0.25% trypsin-
EDTA in Hank’s balanced salt solution and incubated at 37 °C for 4 h. Two μL samples 
were taken at 1 and 4 h, spotted on chromatography paper with a PBS mobile phase, and 
analyzed for metabolite migration. Integration analysis was again used to determine the 
relative percentage of Gp2 metabolites. 
4.3.9 Tissue Quantification of 64Cu-NODAGA-GαE22, -GαE35, and -GαE57 in Mice 
Bearing A431 and MDA-MB-435 Tumor Xenografts 
Mice were anesthetized with 2% isoflurane at 1 mL min-1 oxygen until stationary. 
When no longer ambulatory, 1.0-1.9 MBq 64Cu-NODAGA-GαE22, -GαE35, or -GαE57 
was injected via lateral tail vein. At 2 h p.i., mice were again anesthetized then euthanized 
by cervical dislocation. After confirming expiration by toe pinch, mice were dissected and 
blood, heart, lung, liver, pancreas, spleen, stomach, intestine, skin, brain, bone, muscle, 
kidney, A431, and MDA-MB-435 were extracted and weighed. Resected samples were 
measured for radioactivity by a CRC-25W (Capintec, Florham Park, NJ) gamma counter 
across all energy ranges and averaged over 1-2 min. Incident counts were calibrated using 
serial dilutions based on the dose reported by an Atom Lab dosimeter. 
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4.3.10 PET Imaging/Quantification and Tissue Quantification of 64Cu-NODAGA-
GαE35 in Mice Bearing Dual A431 Tumor Xenografts 
Mice were anesthetized as described previously. Upon loss of motor function, mice 
bearing dual A431 tumors were injected via lateral tail vein with 0 or 0.7 – 0.8 mg 
NODAGA-GαE35 followed 5-10 min later by 1.0-2.7 MBq 64Cu-NODAGA-GαE35. 
Injected radioactivity was quantified by an Atomlab 100 dosimeter (Biodex, Shirley, NY) 
calibrated for 64Cu measurements. Static PET scans were performed at 1 and 2 h post-
injection on an Inveon microPET/CT (Siemens, Malvern, PA) and images reconstructed 
with the 2D ordered-subset expectation maximization (OSEM2D) method using four 
iterations of Fourier rebinning. Photopeak energy cutoffs were 350-650 keV with a timing 
window of 3.437 ns. A 1 x 1 x 1 voxel Gaussian filter was used to smooth PET images. 
Concomitant CT scans were completed using 340 projections of 80 kV at 500 µA with 4 x 
4 binning, 200 ms exposure over 384 s total scan time, and an effective pixel size of 85.6 
μm. CT scans were reconstructed with the Feldkamp–David–Kress algorithm using slight 
noise reduction and Shepp-Logan filtering. PET image ROI quantification was performed 
on Inveon Research Workplace software (Siemens) using CT images as guides to 
determine 3D margins for tissues of interest including liver, thigh muscle, kidneys, and 
A431 tumors. The maximum average PET signal in a 3 × 3 × 3 spherical voxel (9.1 mm3) 
was calculated for each tissue of interest.  
Two hours after 64Cu-NODAGA-GαE35 injection, mice were euthanized, tissues 




Comparisons for statistical significance between was determined using two-tailed 
Student’s t-tests assuming unequal variance between sample data sets. Data are presented 
as mean ± standard error unless otherwise noted. 
4.4. Results and Discussion 
4.4.1 Mutant Library Design and Construction 
To identify functional mutants of the EGFR-binding Gp2 (GαE2.2.3, also termed 
GαE57 since it is a Gp2 ligand targeting EGFR with five basic and seven acidic residues) 
with modified charge distributions, we constructed combinatorial libraries for high-
throughput functional screening in which the ten charged sites present in the framework 
were diversified. We also aimed to identify charge mutations that are broadly acceptable 
within numerous engineered variants of the Gp2 scaffold (Figure 4-1A); thus we created 
additional libraries for insulin receptor and rabbit IgG binding based on previously 
established GαI2.2.5
150 and GαR3.2.3
149 ligands. In all three cases, charged residues in the 




Figure 4-1. Gp2 charge distribution. (A) Structure of the wild-type Gp2 scaffold with 
acidic (blue), basic (red), and paratope (green) residues highlighted [PDB: 2WNM134] 
(B) Sequences of wild-type, EGFR-, InsR-, and rIgG-binding clones used as parental 
ligands for charge modified Gp2 libraries. 
Full amino acid diversity would necessitate 2010 = 1013 unique clones and surpass 
the transformation efficiency of yeast used for protein display and selection. Therefore, a 
more selective approach was undertaken to predict which newly introduced mutations 
would be least likely to impair protein folding and target binding. Three metrics were 
applied: lack of destabilization as predicted by FoldX245, frequency in natural 
homologs163,164, and amino acid hydrophilicity246. FoldX was used to compute the 
theoretical change in stability upon independent mutation of each charged site (details in 
Experimental Procedures), which predicted that several charged positions would be 
relatively intolerant to mutation without negatively affecting fold (Figure 4-2A). These 
include sites 1, 14, 24, 42, and 44 where 9-14 mutations away from wild-type amino acids 
increased free energy of folding in excess of 0.5 kcal mol-1. The remaining charged 
positions (20, 23, 27, and 30) were more amenable with only 1-6 mutations causing a 
similar increase in free energy.  
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Amino acid frequencies from Gp2 homologs (Figure 4-2A), identified via search 
of available genomes, also provided information regarding potentially acceptable 
mutations at charged positions. Wild-type residues were generally conserved with an 
average of 3.2 non-wild-type amino acids observed. This value decreased to 2.4 when 
excluding replacement with amino acids of identical charge. Sites 1, 14, 24, 30, 42, and 44 
had high conservation of wild-type amino acids (≥ 75% consensus) whereas sites 20, 27, 
and 31 were more amenable to neutralization, accepting several neutral functional groups. 
Site 23 was highly conserved as a negatively charged residue but relatively indifferent to 
aspartic (56%) or glutamic (41%) acid. 
 
Figure 4-2. Combinatorial library design. (A) Theoretical stability upon mutation 
based on FoldX245 force field calculations, natural homolog frequencies from the 
BLAST algorithm250, and amino acid hydropathy246. (B) Example of the decision-
making process behind library designs. (C) EGFR-, InsR-, and rIgG- charge modified 
Gp2 libraries as designed. 
Each charged position required individual analysis such that no metric 
(hydrophilicity, stability, and homolog frequency) was applied universally to identify 
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reasonable mutants for inclusion in the library. All charged functional groups extend 
outside of the protein core in the wild-type structure134 making high to moderate 
hydrophilicity preferable. Additionally, an elevated frequency in naturally occurring 
homologs guided inclusion of neutral amino acids in the combinatorial library design. 
Finally, mutations causing a considerable increase in free energy of folding (ΔΔGfolding ≥ 1 
kcal mol-1), as modeled by FoldX, were avoided unless such mutations presented high 
homolog frequency (> 5%) and low hydrophobicity (< -1). In some instances, the inclusion 
of less desirable amino acids was unavoidable due to genetic code restrictions. The 
following examples are used to demonstrate the overall methodology. Site 1 was allowed 
to mutate to glutamine for high hydrophilicity, leucine for elevated homolog frequency, 
and isoleucine as a byproduct of lysine and leucine codons (Figure 4-2B). In some cases, 
mutations that appeared nondetrimental in one metric would be juxtaposed by the others. 
For example, methionine was deemed generally acceptable at all sites of interest via 
stability analysis (median ΔΔGfolding, mutation = -0.4 kcal mol
-1) although it is moderately 
hydrophobic and has a mere 4% homolog frequency at site 31 and 0% frequency elsewhere. 
Similarly, hydrophilic proline was predicted to be destabilizing at position 44 
(ΔΔGfolding,mutation = 3.7 kcal mol
-1), but presented 9% sequence identity in natural 
homologs. The high throughput of yeast display and flow cytometry for functional 
selection enabled analysis of many mutants while the combinatorics of diversifying 10 
positions required exclusion of many others. 
Genes containing the degenerate codons necessary to implement these charged site 
mutations (Figure 4-2C), unmutated backbone residues, and EGFR-, InsR-, or rabbit IgG-
binding paratopes were constructed through overlap PCR of 8-11 oligonucleotides per 
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library resulting in 0.75 x 106, 0.75 x 106, and 1.7 x 106 possible unique clones. Assembled 
genes were electroporated into EBY100 S. cerevisiae yeast along with a linearized vector 
to enable yeast display of Gp2 as a C-terminal fusion to Aga2p with a glycine-rich 
polypeptide linker.167,255 The resultant yields of 2 x 108, 1.7 x 108, and 2.1 x 108 
transformants for EGFR, InsR, and rabbit IgG libraries allow for >99% sampling of 
theoretical sequence space.256 Illumina MiSeq deep sequencing of naïve libraries showed 
that 91%, 94%, and 88% of EGFR, InsR, and rIgG yeast transformants presented sequences 
as designed. These values increase to 98-99% when single-point mutations are included, 
indicating high library quality. 
4.4.2 Mutant Selection 
EGFR, InsR, and rIgG libraries were sorted, via yeast display and flow cytometry, 
to isolate mutants that retain stability and functional binding. The yeast containing the 
genetic libraries were grown and induced to express the Aga2p-linker-Gp2 variants 
tethered to their surface via covalent linkage to the membrane-bound Aga1p mating 
protein.167,255 Gp2-displaying yeast libraries underwent consecutive rounds of 
fluorescence-activated cell sorting (FACS) in which yeast were placed at an elevated 
temperature to induce unfolding of unstable mutants177, incubated on ice with target 
protein, and evaluated for retention of activity. Parental library ligands GαE2.2.3, GαI2.2.5, 
and GαR3.2.3, each demonstrated target affinities in the low nanomolar range (18 ± 8, 2.4 




Table 4-1. Library sorting conditions for charge mutated Gp2 libraries with parental 
clone in vitro characteristics.  
 
These values were used to guide temperature and target concentration stringency during 
sorts. Naïve libraries exhibited a broad distribution from mutants that lost function to 




Figure 4-3. First generation library selections. Naïve (A, B, C) and terminal (D, E, F) 
GαE, GαI, and GαR populations sorted for stability and binding with (black) and 
without (gray) their respective recombinant target. 
To remove instances of highly unstable or nonbinding variants, naïve libraries were 
initially sorted at mild conditions with thermal stress temperatures 10 °C or more below 
parental Tm and recombinant target at (EGFR, rIgG) or above (InsR) parental dissociation 
constants (Table 4-1 and Materials and Methods). A subsequent set of sorts aimed to isolate 
populations that either demonstrate improved thermal stability while maintaining moderate 
affinity (via elevated thermal stress with maintained target concentration) or provide 
increased ligand affinity after mild thermal stress (maintained thermal stress 11-28 °C 
below parental Tm while reducing target concentration). To this end, the sorted populations 
were split and sorted separately at each condition set, then pooled. Compared to GαI and 
GαR libraries, anti-EGFR clones were quite robust in their response to stability and affinity 
selection pressures and were sorted an additional time at an elevated temperature (80 °C) 
and low target concentration (2 nM).  Although parental GαI2.2.5 and GαR3.2.3 exhibit 
substantial stability (78 and 80 ± 2 °C), no appreciable target-bound populations were 
present above background signal in sorts exceeding 60 °C even at heightened levels of 
target. However, unlike GαI, GαR clones retained parental affinity at 60 °C. To deplete 
clones that exhibit nonspecific binding, enriched populations of Gp2-displaying yeast were 
incubated with streptavidin- and mouse IgG (mIgG)-coated magnetic beads at saturating 
conditions257, and only unbound yeast were retained. 
In each of the three rounds of ligand selection against recombinant EGFR, 4-6% of 
sorted populations were collected based on expression-normalized target binding as 
indicated by triangular gates (Figure 4-4). To prepare for use in physiological 
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environments, we aimed to ensure that mutants bound EGFR in its native fold. Thus, the 
EGFR-binding population underwent two additional rounds of sorting without heating 
against 2 and 0.2 nM solubilized EGFR from the lysate of A431 epidermoid carcinoma 
cells (2 – 6% collected).  
 
Figure 4-4. Enrichment of stable, EGFR-binding charge mutants. Yeast libraries 
displaying charge-modulated Gp2 ligands were sorted against biotinylated EGFR 
ectodomain (2 – 20 nM) after preheating the yeast for 30 min (60 - 80 °C) followed by 
screening against streptavidin- and mIgG-coated beads to deplete nonspecific 
binders, and finally sorted against lysate-extracted EGFR at 2 and 0.2 nM target. 
EGFR-labeled and target-negative yeast are shown in red and black with collected 
populations in triangular gates. 
4.4.3 Mutant Characterization  
Plasmids from the starting libraries and the concluding functional populations 
sorted for thermal tolerance and recombinant target binding, after nonspecific Gp2 ligand 
depletion, were sequenced via Illumina MiSeq. Additionally, 24 clones from solubilized 




Figure 4-5. Net and total charge distributions of clones in naïve and sorted populations. 
(A, B) EGFR (naïve: 2705, sorted: 3202), (C, D) InsR (naïve: 2842, sorted: 798), and 
(E, F) rIgG (naïve: 596, sorted: 172) Gp2 libraries. Data presented as frequency ± 
standard deviation. Mean ± standard deviation of overall distribution shown in 
legend. 
In the EGFR case, negatively charged variants were enriched during functional 
selection as the mean net charge shifted from neutral (0.1 ± 1.6) in the unsorted library to 
-2.7 ± 1.4 in the functional pool (Figure 4-5A). Notably, this shift was in the direction of 
— and past — the parental GαE57, which has a net charge of -2. This net charge shift was 
achieved via enrichment of wild-type acidic residues as well as neutralization of basic 
residues: the unsorted library neutralized more than six sites on average (GαE57 has 12 
charged sites whereas the unsorted library has 5.6 ± 1.6), which only slightly increased in 
the functional pool (7.0 ± 1.4), indicating that the larger shift in net charge also had 
contributions from neutralization of basic residues (Figure 4-5B). Sitewise analysis reveals 
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the specifics of these functional preferences (Figure 4-6), which are discussed below in the 
context of all domains. 
The other two parental Gp2 domains exhibit divergent tolerances to charge 
reduction as GαI essentially maintains removed charge (6.7 ± 1.3 charged sites in 
functional domains relative to 6.4 ± 1.4 in the library and 12 in the parental domain) 
whereas GαR reverts nearly half of its removed charges (3.3 ± 1.4 naïve to 5.4 ± 1.4 in 
functional vs. 8 in parental). Akin to the EGFR-targeted domain, but to a lesser extent, 
GαR net charge evolved toward the negative parental. The lack of change in total charge 
of GαI is matched by an absence of movement in net charge (-3.8 ± 1.5 in naïve vs. -3.6 
± 1.5 in functional populations). Notably, unlike the other libraries, the GαI library starts 
as net negative because of four acidic residues and no bases in its evolved loops. One other 
possible explanation for the tolerance of charge removal in GαI is an increase in structural 
stability imparted by a predicted disulfide bond between C8 and C38 in the evolved loops.  
Across all three targets, the six negatively charged sites exhibit enrichment of the 
parental acidic side chains, with an increased frequency in functional variants of 29 ± 20%, 
with E14 and D23 in the InsR-targeted domains being the lone exceptions. Positively 
charged sites showed greater variance. Positions 1 and 31 display functional preference 
toward neutral residues frequent in natural homologs. K1 evolved toward leucine in all 
campaigns, which is present in 13% of native Gp2 homologs. Position 31, which is only 
charged in the parental EGFR-binding domain, preferentially mutates to W, which is 56% 
W in native homologs. R42 exhibits nearly comparable preference of Q and R within 
EGFR-binding domains whereas InsR- and rIgG-binding domains strongly enrich wild-
type arginine. R44 exhibits variable performance for each target. EGFR-targeted domains 
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enrich P and tolerate Q at the expense of R; InsR-targeted domains enrich Q and tolerate 
R; rIgG-binding domains enrich R and tolerate Q. 
 
Figure 4-6. Sitewise amino acid functionality. Change in frequencies between 
functional and naïve populations. Parental amino acids presented in black unless 
noted by a matching color change in legend (* indicates presence solely in the rIgG 
library). 
The utility of the combinatorial library approach is evident from the lack of strong 
correlations between functional efficacy and direct design metrics. Sitewise enrichment of 
particular amino acids does not correlate with predicted stability by FoldX (Pearson 
correlation coefficient, R = 0.24) or hydrophilicity (R = 0.01). Consistent with the 
examples in the previous paragraph, modest correlation is evident for natural homologs (R 
= 0.47).  
Overall, numerous members of each library were robust to thermal denaturation 
and sorting against concentrations of recombinant target in the low nanomolar range. 
Additionally, several Gp2 variants bound high picomolar concentrations of A431 lysate-
derived EGFR.  
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4.4.4 Top Clones and In Vitro Characterization 
In addition to revealing mutational preferences, these selections identified 
particular functional mutants. To determine the effects of reducing total charge, six clones, 
all maintaining parental or near-parental net charge, were chosen from the final EGFR 
lysate-sorted population to further characterize the impacts of charge modification as well 
as to identify compelling lead mutants for physiological study.  
These variants, with charge states of +2/-2, +2/-4, +2/-5 (two clones), +3/-5, and 
+3/-6, were produced in T7 E. coli and evaluated in vitro for soluble production yield, 
target affinity, thermal stability, and secondary structure. (Table 4-2). 
Table 4-2. Mutated positions, paratope (loop) sequences, and in vitro characteristics 
of Gp2 clones recovered in flow cytometry sorts against EGFR derived from A431 
cell lysate. Kd values represent equilibrium dissociation constants from titrations of 
mutants against A431 cells using flow cytometry (n = 3). Midpoint denaturation 
temperatures (Tm) were determined with circular dichroism spectroscopy of purified 
proteins (n = 1 - 3). Yield is reported as recovered mass of purified protein per L of 
culture (n = 3). 
 
Soluble production yield was diminished considerably for GαE24 and GαE25B 
with less than 0.05 mg/L recoverable for either clone. However, recovery in the remaining 
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four mutants exceeded 1 mg/L allowing for further in vitro characterization. As selected 
for, all four mutants exhibited good binding affinity (Figure 4-7).  
 
Figure 4-7. Anti-EGFR Gp2 affinity titrations. A431 cells were incubated on ice with 
2, 6, 20, 50, or 500 nM Gp2 ligand followed by labeling with fluorescein-conjugated 
anti-His6 antibody and median fluorescence analysis via flow cytometry. Equilibrium 
dissociation constants were calculated using a 1:1 binding model (n = 3). 
Compared to GαE57, charge reduced clones GαE25A and GαE36 demonstrated 
nominally improved target affinity against recombinant EGFR (9.4 ± 4.1 nM for parental 
vs. 4.9 ± 0.7 nM (GαE25A) and 2.3 ± 1.1 nM (GαE36)) while GαE22 and GαE35 
maintained near parental values (6.3 ± 1.4 nM and 8.8 ± 0.6 nM). Conversely, the mutants 
diverged with regard to thermal stability. GαE35 improved upon parental stability (Tm = 
87 ± 1 °C) whereas GαE25A, GαE22, and GαE36 saw 15-20 °C reductions in melting 




Figure 4-8. Anti-EGFR Gp2 thermal denaturation curves. Purified ligands were 
scanned at a wavelength of 220 nm during heating from 20 to 98 °C (2 °C/min). The 
midpoint of denaturation (T
m
) was determined using a two-state protein unfolding 
model. 
Secondary structure was reasonably maintained in all variants (Figure 4-9). 
GαE25A showed a slight shift toward increased -helical content. Interestingly, clones that 
did not fully return to their original secondary structure after heating (GαE25A, GαE22, 
GαE36) also exhibited a demonstrable decrease in Tm when compared to fully refoldable 




Figure 4-9. Circular dichroism spectroscopy of recovered mutants. Purified anti-EGFR 
Gp2 mutants were analyzed by circular dichroism spectroscopy in triplicate between 
205 and 260 nm wavelengths before (- - -) and after (–––) thermal denaturation and 
cooling. 
Five of the six clones analyzed were either not appreciably producible or saw a 
significant reduction in Tm. This suggests that more stringent thermal denaturation 
temperatures prior to sorting against target and perhaps an increase in the number of 
individually assessed clones may be required to isolate more useful ligands. Nevertheless, 
a mutant (GαE35) was identified that reduces total charge by four and alters charge 
distribution (Figure 4-10) while maintaining net charge, elevates thermal stability, 
maintains binding affinity, and retains recombinant yield. In addition, a mutant (GαE22) 
was identified with greatly reduced total charge and maintained binding affinity albeit with 




Figure 4-10. Expected structure and sequence of GαE35. (A) Approximate structure, 
based on PDB: 2WNM134, and sequence of the GαE35 ligand with acidic (blue), basic 
(red), and paratope (green) residues highlighted. 
4.4.5 Physiological Distribution and Protease Degradation 
To ascertain the effects that reduced and redistributed charge may impart on an 
EGFR-binding ligand in vivo, GαE22, GαE35, and parental GαE57 were chosen as 
candidates for imaging of tumor-bearing murine models. GαE35 retains parental net charge 
of -2, providing an opportunity to elucidate the effects of a reduction in total charge. GαE22 
is the least charged anti-EGFR Gp2 isolated from the selections creating a more extreme 
comparison between GαE57 and a substantially charge-reduced variant. To address target 
specificity, A431 ((2.9 ± 1.4) × 106 EGFR per cell227) and MDA-MB-435 ((1.5 ± 1.1) × 
104 EGFR per cell227) were incubated with 500 nM GαE22, GαE35, or GαE57 and analyzed 
via flow cytometry. Binding to A431 cells was substantially higher than to MDA-MB-435 




Figure 4-11. EGFR binding specificity. MDA-MB-435 (EGFR
low
) and A431 
(EGFR
high
) cells were incubated on ice with 500 nM Gp2 ligand, labeled with 
fluorescein-conjugated anti-His
6
 antibody, and median fluorescence signal 
determined with flow cytometry (n = 3) (* signifies p ≤ 0.001). 
While all clones exhibited strong differentiation between the cell types, binding to 
EGFRlow MDA-MB-435 cells was significantly lower for GαE35 than the parental GαE57 
(p < 0.001), and at a ratio consistent with reduced EGFR expression, which suggests 
enhanced specificity for the charge-engineered GαE35. These clones were conjugated with 
the metal ion chelator NODAGA through an amine-reactive cross-linking reaction with its 
N-hydroxysuccinimidyl ester. Labeling was nonspecific due to the free amines present on 
lysines at position 1 of GαE57 and 27 of GαE35. However, conjugation was on average 
singular with 0.9 ± 0.2, 1.1 ± 0.2, and 1.1 ± 0.4 NODAGA per molecule for GαE22, GαE35, 




Figure 4-12. Conjugation of NODAGA to Gp2 charge variants. Matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS) of NODAGA-conjugated 
GαE22, GαE23, and GαE57. 
NODAGA-conjugated ligands were mixed with 1-2 mCi of 64Cu in 100 mM 
sodium acetate, pH 6.0 at 42 °C for 60 min. Complexed 64Cu was separated from free 
copper via size exclusion filtration resulting in 38-48% labeling efficiency and 87-98% 




Figure 4-13. Proteolytic stability. Radio-thin-layer chromatography of radiolabeled 
GαE clones left untreated, in serum, or trypsin. 
Based on yields from previous purifications of unlabeled Gp2 ligands, approximate 
specific activities were calculated as 0.5-1.2 MBq nmol-1. Physiological biodistribution of 
each radiolabeled ligand was ascertained by injecting 1.3 ± 0.3 MBq into mice (n = 5-6) 
bearing EGFRhigh A431 and EGFRlow MDA-MB-435 tumors. Two hours after injection 
tissues were excised, weighed, and measured for radioactivity (Figure 4-14). 64Cu-
NODAGA-GαE57 and 64Cu-NODAGA-GαE35 localized strongly to EGFR-
overexpressing A431 cells, displaying 5.5 ± 0.5 %ID/g and 4.7 ± 0.5 %ID/g. Binding was 
target specific (p < 0.01) with 0.9 ± 0.1 %ID/g and 0.6 ± 0.1 %ID/g on EGFRlow MDA-
MB-435 tumors for 64Cu-NODAGA-GαE57 and 64Cu-NODAGA-GαE35, respectively. 
This improved in vivo specificity of 64Cu-NODAGA-GαE35 (p = 0.01) is consistent with 
reduced nonspecific binding in vitro (Figure 4-11). TumorEGFR-high:tumorEGFR-low, 
tumor:blood, and tumor:muscle ratios were all strong and nominally higher for the charge-
reduced 64Cu-NODAGA-GαE35 (Figure 4-14, inset). As with many small protein probes, 
renal signal is elevated. 64Cu-NODAGA-GαE57 has modestly lower renal signal than 64Cu-
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NODAGA-GαE35, 153 ± 25 %ID/g vs. 209 ± 18 %ID/g, respectively. Liver activity is 
slightly elevated for both 64Cu-NODAGA-GαE57 (2.6 ± 0.1 %ID/g) and -GαE35 (3.0 ± 
0.3 %ID/g), but background signal remains below 2 %ID/g for the remaining tissues 
sampled. 
 
Figure 4-14. Excised tissue analysis of charge modified GαE ligands. Mice xenografted 
with A431 (EGFRhigh) and MDA-MB-435 (EGFRlow) tumors on opposing shoulders 
were intravenously injected with 64Cu-NODAGA-GαE57, 64Cu-NODAGA-GαE35, or 
64Cu-NODAGA-GαE22 and euthanized 2 h post-injection. Tissues or fluid of interest 
were extracted, weighed, and gamma decay radioactivity measured (%ID/g) (n = 5 – 
6). *: p < 0.05. Inset represents ratios of tumor:background signal. 
Conversely, 64Cu-NODAGA-GαE22 was not an effective EGFR ligand in vivo. 
A431 tumor signal was nearly 2-fold lower than that of GαE57 and GαE35 clones. 
Additionally, off-target retention was statistically higher in blood, heart, lung, liver, spleen, 
and bone samples (p < 0.05). Background signal was most pronounced in the liver where 
64Cu-NODAGA-GαE22 displayed 8.4 ± 1.0 %ID/g, approximately 3-fold higher than 
64Cu-NODAGA-GαE57 and 64Cu-NODAGA-GαE35. While this broad background could 
be related to slightly increased nonspecific binding (Figure 4-11), the co-occurrence of 
reduced EGFRhigh tumor localization is more consistent with molecular instability. The 
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propensity to enzymatically degrade was determined in vitro by adding 64Cu-NODAGA-
GαE22, -GαE35, and –GαE57 to murine serum, human serum, or 0.25% EDTA-trypsin at 
1:20 volumetric ratios and heating at 37 °C for 4 h. Radio-thin-layer chromatography of 
samples taken at 1 and 4 hours post-mixing was used to determine the relative amounts of 
proteolytic metabolites (Figure 4-13). 64Cu-NODAGA-GαE22 was highly unstable with 
59% and 50% cleavage in human and murine serum after 1 h. These values increased to 
80% and 68% by 4 h. 64Cu-NODAGA-GαE35 and 64Cu-NODAGA-GαE57 were more 
resistant to enzymatic degradation in serum. Proteolysis of 64Cu-NODAGA-GαE35 and 
64Cu-NODAGA-GαE57 in human and murine serum resulted in 10% and 17% and 10% 
and 26% degradation by 1 h, respectively. All clones were degraded to near completion (≥ 
92%) in EDTA-trypsin after 4 h. In retrospect, the proteolytic instability of GαE22 may 
have been predicted by its decreased Tm compared to GαE35 and GαE57. 
4.4.6 Positron Emission Tomography Imaging of GαE35 
In contrast to parental 64Cu-NODAGA-GαE57, 64Cu-NODAGA-GαE35 showed 
statistically lower MDA-MB-435 signal, similar A431 retention and off-target uptake, and 
nominal improvements in tumor:blood and tumor:muscle ratios. Buoyed by these results, 
PET/CT imaging of 64Cu-NODAGA-GαE35 was performed in murine models bearing 
A431 xenografts, with dual tumors to increase experimental observations of tumor uptake 
and retention. To further evaluate target specificity, imaging was performed with and 
without preblocking by an injection of unlabeled NODAGA-GαE35. Copper chelation of 
64Cu-NODAGA-GαE35 and purification were performed as previously described resulting 
in 66% labeling efficiency, 97% radiochemical purity, and 1.43 ± 0.01 MBq nmol-1 specific 
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activity. To demonstrate native EGFR specificity, four mice were intravenously injected 
with unlabeled NODAGA-GαE35 at 87 – 144-fold molar excess (0.7 – 0.8 mg) followed 
by 1.5 ± 0.4 MBq of 64Cu-NODAGA-GαE35 between 5 and 10 min later. Four separate 
mice were injected with 1.9 ± 0.7 MBq of 64Cu-NODAGA-GαE35 without blocking by 
unlabeled ligand. CT/PET scans were performed at 1 and 2 h post-injection (Figure 4-15A). 
Using CT scans as an anatomical guide liver, muscle, tumor, and kidney signals were 
quantified through PET image analysis at both time points (Figure 4-15B). 64Cu-
NODAGA-GαE35 localized to EGFR-overexpressing A431 tumors (5.6 ± 0.6 %ID/g) and 
cleared background (7.2 ± 1.1 tumor:muscle ratio) within 60 min. Tumor signal (6.2 ± 0.6 




Figure 4-15. PET/CT imaging and PET image quantification. (A) Mice xenografted 
with two A431 (EGFRhigh) tumors on opposing shoulders were intravenously injected 
with either 64Cu-NODAGA-GαE35 (Nonblocked) or NODAGA-GαE35 at (102 ± 29)-
fold molar excess followed by 64Cu-NODAGA-GαE35 5 - 10 min later (Blocked) and 
imaged via PET/CT at 1 and 2 h post-injection. Coronal and transverse slices through 
tumors are shown for representative mice (n = 4). (B) Signal in the liver, muscle, 
tumors, and kidney were quantified using Siemens Inveon research software at 1 and 





Binding was target specific as demonstrated by a nearly 2-fold reduction in tumor 
signal when pre-blocked with excess NODAGA-GαE35 at both 1 (2.9 ± 0.3 %ID/g) and 2 
h (2.8 ± 0.4 %ID/g) (p < 0.01). Muscle retention was low and indifferent to injection 
scheme at 1 h (1.3 ± 0.2 vs. 0.8 ± 0.1 %ID/g) and 2 h (0.9 ± 0.1 vs. 0.9 ± 0.1 %ID/g) for 
mice with or without cold NODAGA-GαE35 blocking. Hepatic signal was elevated 
relative to muscle in blocked (4.4 ± 0.4 %ID/g) and nonblocked (4.5 ± 0.6 %ID/g) models 
after 1 h, remained constant at 2 h in blocked models (4.0 ± 0.8 %ID/g), and increased 
modestly at 2 h in nonblocked mice (5.6 ± 0.5 %ID/g). Consistent with biodistribution 
analysis of other small protein ligands94,129,214,254,259, kidney signal is elevated due to renal 
processing. Renal uptake was 1.5x and 1.6x higher in nonblocked mice at 1 and 2 h. Note 
that due to high levels of photon emission within the kidneys, multiple coincident events 
may be observed within the given collection time window and therefore discarded, leading 




Figure 4-16. Excised tissue analysis of 64Cu-NODAGA-GαE35 with and without 
blocking by NODAGA-GαE35. Mice (n = 4) xenografted with two A431 (EGFRhigh) 
tumors on opposing shoulders were intravenously injected either 64Cu-NODAGA-
GαE35 (Nonblocked) or NODAGA-GαE35 at (102 ± 29)-fold molar excess followed 
by 64Cu-NODAGA-GαE35 5 - 10 min later (Blocked). Mice were euthanized 2 h post-
injection. Tissues or fluid of interest were extracted, weighed, and gamma decay 
radioactivity measured (%ID/g) (*: p < 0.05; **: p < 0.001). 
Two hours post-injection, mice were euthanized with tissues of interest excised, 
weighed, and measured for radioactivity (Figure 4-16). PET image quantifications were 
corroborated by tissue measurements. 64Cu-NODAGA-GαE35 exhibited strong EGFR-
specific uptake (5.0 ± 0.7 %ID/g nonblocked vs. 2.5 ± 0.2 %ID/g blocked; p < 0.001), 
elevated tumor:blood (9.2 ± 1.9 %ID/g nonblocked vs. 2.3 ± 0.3 %ID/g blocked; p < 0.001) 
and tumor:muscle (25 ± 11 %ID/g nonblocked vs. 8.7 ± 2.4 %ID/g blocked; p < 0.001) 
ratios. 64Cu-NODAGA-GαE35 tumor signal was nominally higher when quantified via 
image analysis versus excised tissue scintillation (6.2 ± 0.6 %ID/g vs. 5.0 ± 0.7 %ID/g), 
although this difference was not statistically significant. Additionally, muscle signal was 
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slightly increased in both blocked (0.9 ± 0.1 %ID/g vs. 0.3 ± 0.0 %ID/g) and nonblocked 
(0.9 ± 0.1 %ID/g vs. 0.2 ± 0.0 %ID/g) images. 
4.5. Conclusions 
We created combinatorial libraries through rational design to introduce charge-
neutralizing or charge-flipping mutations on the Gp2 scaffold. By briefly heating yeast-
displayed Gp2 domains to denature unstable clones followed by flow cytometry to sort for 
the retention of binding, deep sequencing of the enriched populations revealed preferred 
mutations across three diverse binders (to EGFR, InsR, and rIgG). Functional populations 
indicated tolerance of substantial charge removal with a propensity toward reintroduction 
of charge and a maintenance of negative net charge. Additional screening identified a 
promising EGFR Gp2 ligand with improved charge distribution, reduced charge density, 
high stability, and strong, specific binding. Three lead EGFR binders, GαE22, GαE35, and 
parental GαE57, were conjugated with NODAGA, complexed with 64Cu, and analyzed in 
vivo using murine models bearing EGFRhigh and EGFRlow tumors. NODAGA-GαE35 
demonstrated good EGFRhigh tumor localization (4.7 ± 0.5 %ID/g) and, relative to parental 
NODAGA-GαE57, improved specificity with reduced EGFRlow uptake (0.6 ± 0.1 vs. 0.9 
± 0.1 %ID/g, p = 0.01) and nominally improved tumor:blood (9.7 ± 1.3 vs. 6.2 ± 2.0), 
tumor:muscle (35 ± 5 vs. 23 ± 7), and EGFRhigh:EGFRlow (8.1 ± 1.2 vs. 6.1 ± 0.9) ratios. 
Further study with additional mutants will be needed to more broadly assess the impact of 
charge reduction and redistribution on ligand performance. Our study allows for the 
enhancement of the Gp2 framework through guided charge modulation, validates a method 
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to engineer these modifications, and provides a lead clone, GαE35, to advance 
physiological EGFR targeting for the purpose of molecular imaging. 
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Chapter 5  - Concluding Remarks and Future Work 
Protein charge – net, density, and distribution – is an important physicochemical 
property that impacts developability and efficacy of biologics. Yet charge manipulation is 
a challenging task, particularly in the context of small protein ligands, which otherwise 
provide advantages in physiological distribution relative to antibodies, particularly for 
diagnostic molecular imaging. This thesis describes the charge engineering of affibody and 
Gp2 scaffolds through the creation of rationally guided clones and combinatorial libraries 
which were screened for stability, recombinant yield, and target affinity; deep-sequenced 
to determine preferred charge distributions and site-specific mutations; and lead clones 
evaluated in vivo as molecular imaging probes for the commonly overexpressed cancer 
biomarker, EGFR. 
To evaluate the impact of protein charge on the affibody scaffold, a hybrid clone 
‘EA68’ was formed through the incorporation of an anti-EGFR paratope into a stabilized 
affibody framework. Of the charge engineering techniques utilized to modify EA68, 
synthetic consensus design proved most robust, providing a clone (EA35S), which 
neutralized three acidic and three basic residues, with yields and stability comparable to 
EA68 and an increased EGFR affinity (1.7 ± 0.5 nM vs. 5.3 ± 1.7 nM). The utility of 
synthetic consensus design was further validated through its application in the creation of 
additional EA35S-based clones carrying +6/-2 and +2/-6 charge states which retained 
parental EGFR affinity and secondary structure with only a slight reduction in thermal 
stability for the +6/-2 variant. Charge engineering of the Gp2 scaffold relied upon diverse 
combinatorial libraries for charge-neutralizing and charge-flipping mutations introduced 
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into InsR-, rIgG-, and EGFR-targeted domains. Enriched populations demonstrated target-
dependent total, net, and site-specific charge preferences. Average formal and total charge 
states in recovered populations typically migrated towards or remained at parental values, 
but differences across libraries suggest charge-modifying diversity may not be uniformly 
accepted even within the same scaffold type. These results reinforce the utility of synthetic 
consensus design as a puissant tool for protein charge engineering with neutral or beneficial 
impact on primary function and biophysical properties. Additionally, site-specific amino 
acid regulation across libraries with varied targets may be a better predictor of globally 
accepted mutations, providing insight into an improved scaffold framework for novel 
clones against additional biomarkers of interest. 
During independent affibody and Gp2 experiments, lead anti-EGFR ligands 
EA35S, GαE35, and their charge-varied homologs were evaluated as PET imaging agents 
in mouse models bearing EGFRhigh and EGFRlow xenografts to determine the effect of total, 
net, and distribution of charge on ligand efficacy in vivo. A comparison of radiometal 
chelator moieties using EA35S and EA68 affibodies revealed that, when compared to 
DOTA, 64Cu complexation with NODAGA yielded a simultaneous increase in tumor 
retention and decrease in background tissue signal, elevating disease state imaging contrast. 
The sole net positive affibody tested, EA62S, exhibited 2 – 3-fold higher liver and spleen 
signal comparatively. In contrast to GαE35 and GαE57 – and ostensibly due to molecular 
instability – net neutral GαE22 performed poorly and presented less than half of the tumor 
signal with significantly higher background tissue retention. Although further experimental 
validation in required, these outcomes advocate for the monitoring of proteolytic 
susceptibility in charge mutants and indicate that an increased positive charge may be lead 
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to undesirable hepatic retention. The greatest overall in vivo performance was achieved by 
64Cu-NODAGA-EA35S and 64Cu-NODAGA-GαE35 at 4 and 2 h p.i., respectively. EA35S 
and GαE35 displayed high (12 ± 2 %ID/g and 5.5 ± 0.5%ID/g) and specific (tumor:muscle 
= 34 ± 5 and 35 ± 5; tumor:blood = 12 ± 3 and 9.7 ± 1.3) EGFRhigh tumor localization.  
EA35S and GαE35 show promise as molecular imaging agents and their clinical 
implementation may address the need for noninvasive, patient stratifying PET probes. 
However, dose toxicity and immunogenicity should be determined to prevent adverse 
patient side effects. A direct in vivo comparison between EA35S, GαE35, and an alternative 
EGFR-contrast agent such as Ac-Cys-ZEGFR:1907
213
 which is currently under clinical 
evaluation as a PET/CT radiotracer for non-small-cell lung cancer patients would elucidate 
the probe most likely to succeed clinically. Given its proven stability and efficacy in murine 
models the NODAGA chelator should be retained, but experiments should transition from 
64Cu to 68Ga as radioisotope. Benefits of gallium usage include facile, on-site production 
from 68Ge/68Ga generators260 and a comparatively shorter half-life (~1.1 vs 12.7 h), making 
it suitable for PET imaging at early time points (< 2 h) while decreasing the potential for 
day-scale radioactive dosing to off-target tissues. 
As evidenced by differences in net, total, and site-specific ionic charge biases 
between three, target-distinct Gp2 libraries (Chapter 4), the distribution of framework 
charge may be paratope specific and indicative of a need to sample broader charge-
mutating sequence space in order to recover ligands with both target affinity function and 
desired physicochemical properties. Sequence consensus between populations screened 
against disparate targets illuminates globally acceptable charge modifications while 
individually upregulated clones lead to affinity ligands for molecular recognition of disease 
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state biomarkers. Ongoing and future work combines evolved affibody261 and Gp2262 
paratope regions with scaffold frameworks containing desired redistributions and 
reductions of ionizable residues based on previously determined synthetic consensus 
frequencies. 
Ionic charge affects numerous protein properties yet it is rarely considered during 
discovery and ex post facto modifications are often detrimental to function. The field of 
protein engineering would benefit from preliminary consideration of charge states during 
initial phases of protein design and discovery. Domains with high charge densities and 
structures containing isolated cationic and anionic regions should be avoided. However, 
this type of prescreening may not always be feasible for proteins with unique function or 
for those already in use. In such cases, synthetic consensus design offers a method to 
introduce desired ionizable residue mutations while avoiding detrimental effects on target 
affinity or enzymatic activity. The synthetic design approach described herein relied on 
previously evolved paratopes that may not be available for novel targets. To overcome this 
hurdle, proteolytic challenge of combinatorial libraries using a broad protease such as 
proteinase K can help to determine mutations that retain structural fold and stability. 
Due to their capacity for broad functional diversity, proteins are a protean class of 
biomolecules that have seen significant implementation in catalytic, structural, diagnostic, 
and therapeutic applications. The continued discovery and evolution of proteins with novel 
or improved functionality would be greatly benefited by the enhanced physicochemical 
robustness and tunable in vivo properties achievable through ionic charge engineering. The 
methods and accomplishments described in this thesis make direct contributions towards 
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